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INTRODUCTION 
Roughly 35% patients of insulin-dependent diabetes (IDDM) 
develop diabetic nephropathy. This clinical syndrome is characterized by persis-
tent albuminuria >300 mg/24h, a relentless decline in glomerular filtration rate, 
and elevated blood pressure (Andersen et. al., 1978; Parving et. al., 1981). 
Diabetic nephropathy is a relatively common microvascular complication 
of both insulin-dependent (IDDM) and non-insulin dependent (NIDDM) 
diabetes mellitus. The mortality in patients suffering from diabetic 
nephropathy is upto 100 times that of the age and sex-matched background 
population, and this is mainly due to an enormous excess of deaths from 
end-stage renal disease (Borch-Johnsen et. al., 1985). Arterial hypertension 
enhances the development of diabetic nephropathy and antihypertensive 
treatment reduces albuminuria and diminishes the rate of decline in 
glomerular filtration rate, thereby postponing end-stage renal failure 
in patients with diabetic nephropathy (Parving et. al., 1983; Mogensen 
1982; Parving et. al., 1987). During the past decade, the prognosis of diabetic 
nephropathy has improved substantially probably as a consequence of early 
and aggressive antihypertensive treatment. (Mathiesen et. al. , 1989; 
Parving et. al., 1989). Nevertheless, diabetic nephropathy is still the single 
most important cause of end-stage renal failure in the Western World, 
accounting for over a quarter of all end-stage renal disease (ESRD) in the United 
States. Thus, there is an urgent need to evaluate treatment which may delay 
or even prevent the development of diabetic nephropathy in the sub-
population at risk. Mogensen et. al., 1995, therefore suggested the strategy 
to develop programmes for all patients with diabetes on early detection 
of renal disease followed by intervention. 
Microalbuminuria is the excretion of small quantities of albumin 
(20-200 ug/min) insufficient to be demonstrated by reagent strips. In both 
IDDM and NIDDM, it predicts the onset of proteinuria and chronic renal failure 
(Viberti et. al., 1982; Parving et. al., 1982; Mongensen 1984; Mogensen et. al., 
1986; Jarret et. al., 1984). The association with vascular disease is common 
(Yudkin et. al., 1988; Mogensen 1994; Feldt-Rasmussen et. al., 1994). 
Microalbuminuria is common in poorly treated individuals with essential 
hypertension (Parving H-H et. al., 1974). It is not yet known if screening 
for microalbuminuria and subsequent treatment will improve outcome in 
hypertensive non-diabetic patients or in the general population. In diabetes, 
however, the evidence is strong. 
Several studies suggest that good blood glucose control (HbA,C 
below 7.5-8%) in diabetic patients will preserve renal function and prevent 
development of microalbuminuria (Dahl-Jorgensen et. al., 1994; Krolewski 
et. al., 1995; Viberti 1995; Bujestig et al., 1996). Attained blood pressure and 
rate of progression are correlated in microalbuminuric patients as well as 
in patients with overt renal disease (Mogensen 1994, Parving H-H et. al., 
1994). Intervention studies confirm this (Parving H-H et. al., 1994), so 
careful antihypertensive treatment is recommended. No studies have 
demonstrated a harmful effect of reducing blood pressure below 140/90 mm 
Hg. Most investigations show that blood pressure should be reduced in 
young individuals to 125/80 mm Hg or so along with stabilization of or 
reduction in microalbuminuria. A new concept is "antihypertensive" or 
renoprotective treatment, even when the BP is not at conventional 
hypertensive levels (Bennett et. al., 1995). Treatment should begin with small 
doses, especially in the normotensive and in elderly diabetic patients. 
Titration of antihypertensive therapy can then occur with monitoring of 
urinary albumin and serum creatinine and potassium. Other potential risk 
factors such as plasma lipids and smoking should be evaluated and 
consideration given to intervention. 
A small increase in arterial blood pressure is an early and common 
finding in patients with microalbuminuria (Mathiesen et. al , 1984; Parving 
H-H et. al., 1988; Mathiesen et. al., 1990; Mathiesen et. al., 1986). A rise in 
systemic blood pressure transmitted to the glomerular capillary network 
results in glomerular hypertension (Andersen et. al., 1986), which has also 
been shown in most normotensive rats with streptozotocin induced diabetes 
(Zatz et. al., 1986). A link between raised intraglomerular pressure and 
albuminuria and the development and progression of diabetic renal disease 
has been reported (Hostettor et. al., 1982; Parving H-H et. al., 1983). Acute 
reduction of systemic blood pressure in normotensive patients with persistent 
microalbuminuria reduces albumin excretion (Hommel et. al., 1986), 
probably owing to a reduction in intraglomerular pressure. In diabetic wister 
rats angiotensin-converting enzyme inhibition reduces albumin excretion, and 
slows the development of glomerular structural lesions (Zatz et. al., 1986). 
There is general agreement that so-called normotensive IDDM 
patients (BP<140/90 mm Hg) at age below 60 and <160/90 mm Hg above 
age 60) should receive antihypertensive treatment with an ACE inhibitor as 
soon as microalbuminuria has been clearly confirmed by several tests and provided 
that the best possible blood glucose control has been obtained 
for several months. The longest follow-up trial in young IDDM patients with 
microalbuminuria has been 8 years (Mathiesen et. al., 1995) and long-term 
data on mortality and ESRD (Final end-point) are not yet available. 
There are no formal trials of tight blood-glucose control in NIDDM 
but most experts extrapolate from the DCCT 1993, especially in young 
patients, and Mogensen et. al., 1995 propose that the best possible control 
should be achieved in patients with NIDDM. Antihypertensive treatment 
in "normotensive" microalbuminuric NIDDM patients has not been studied pro-
spectively in trials on large number of patients. One 5-year intervention study 
using ACE inhibition (Ravid et. al., 1993) in young and lean NIDDM 
patient, many of whom were normotensive, noted that microalbuminuria 
was reduced and renal function (Serum creatinine) was preserved. 
The recent publication of another (4-year) prospective study 
supports these findings. Sano et al, 1994 have shown that treatment with enalapril 
(Versus no enalapril) significantly reduced urinary albumin excretion in 
normotensive as well as well-controlled hypertensive NIDDM patients with 
microalbuminuria without altering blood pressure or blood glucose control. 
Together, the observations of Ravid et al, 1994, Sano et al, 1994, and others 
(Marre et al 1988, Kasiske et al, 1993) support a renal protective effect of 
ACE inhibitors in albuminuric non-hypertensive NIDDM patients. These 
findings therefore raise an important and somewhat troubling question. 
Should we as clinicians now advocate lifelong therapy with ACE inhibitors 
to every normotensive NIDDM patient at the sight of trivial amounts of 
albumin traced in their urine? Avs et al, 1996 believe the answer to this 
question lies in a wider circle of as yet unresolved but important issues as 
outlined below: 
i) What does a reduction in urinary albumin excretion of some 100 mg/ 
day after several year of drug therapy mean in terms of the eventual decline in 
renal function and ultimate survival? It is indeed not entirely clear whether 
alterations in urinary albumin excretion necessarily parallel changes in 
glomerular filtration rates or eventual renal prognosis. Furthermore, most 
published studies to date have been short-term (none have exceeded 3 years 
of follow-up) or have included a small number of patients or, more typically, 
both. Since normotensive NIDDM patients with microalbuminuria represent a 
large proportion of NIDDM populations the issue of cost-effectiveness will 
also have to be addressed in any future studies. 
ii) Are ACE-inhibitors truly unique in their acclaimed antiproteinuric 
effects, and should they be considered as first-choice therapy in albuminuric 
NIDDM patients? The answer to this question, surprisingly, may not be as 
conclusive as many might think. While there is generally a body of evidence 
and perhaps a general, at least on, theoretical ground of the "renal-preserving 
characteristics" of ACE inhibitors (especially in patients with IDDM, 
intervention with other antihypertensive agents also has been associated with 
beneficial effects on renal function in NIDDM patients with albuminuria. 
Comparing the effects of perindopril, an ACE inhibitor, and nifedipine, a 
calcium antagonist, in microalbuminuric NIDDM patients, the Melbourne 
Diabetic Nephropathy Study concluded that the two agents had similar effects 
on urinary albumin excretion, both preventing increase in albuminuria in 
normotensive patients and decreasing albuminuria in hypertensive NIDDM 
patients (Melbourne Diabetic Nephropathy Study Group, 1991). Similarly Baba 
et. al, 1989 in a short-term study reported effectively similar renal effects 
in hypertensive NIDDM patients with microalbuminuria who were treated 
with enalapril compared to those treated with calcium antagonist nicardipine. 
Stornello et al, 1992 showed that enlapril and atenolol were equally effective 
in preventing renal decline in normotensive NIDDM patients with persistent 
albuminuria. Thus it is possible that any favourable effects of antihypertensive 
therapy on renal function in albuminuric normotensive NIDDM patients may 
be mediated through a common mechanism inherent to their antihypertensive 
effects rather than being specific to any class of antihypertensive therapy. 
However, the favorable (neutral) metabolic effects of ACE inhibitors 
confer special advantage over other pharmacologic agents, although it is 
equally important to recognise the fact that patients with NIDDM are likely to 
have coexistent hyporeninemic hypoaldosteronism and therefore, are particuarly 
vulnerable to dangerous hyperkalemia with ACE inhibitor use. 
Hi) Atherosclerotic disease remains the primary cause of death in the 
NIDDM population. While albuminuria is reported to be a marker of 
cardiovascular risk in NIDDM patients, it is still not known whether a 
pharmacological amelioration of urinary albumin excretion diminishes the 
high cardio vascular risk observed in these patients. This must await future 
long-term prospective trials. In the meantime, however, the clinical 
management of the NIDDM patient with albuminuria should be based on 
optimization of glycaemic control and a global approach to risk factors, with 
equal attention given to the control and prevention of known risk factors, such 
as smoking cessation and treatment of lipid abnormalities, as well as to 
efforts to halt progression of renal disease(American Diabetic Association 
Consensus Development Conference, 1994). 
The present study reports a relatively long-term, 5-year study of 
the effect of the angiotensin-converting enzyme inhibitor, enalapril, on the 
course of diabetic nephropathy in normotensive IDDM and NIDDM patients 
with microalbuminuria and normal renal function. The report describes a random-
ized, placebo-controlled, double-blind study on 176 diabetic patients. 
REVIEW OF LITERATURE 
Although the discovery of insulin extended and improved the lives oif 
individuals with insulin-dependent diabetes mellitus, it soon became clear that the 
long-term complications of diabetes would result in considerable morbidity and 
mortality. Most physicians accept that hyperglycaemia makes an important contri-
bution to the complications of diabetes mellitus involving small and large vessels, 
but whether hyperglycaemia alone is sufficient to explain the diabetic vascular 
disease remains controversial. Epidemiologic evidence suggests that the end-
organ response to exposure to diabetes, defined as the duration of hyperglycaemia 
multiplied by its degree, differs in different vascular beds. Given time, retinopathy 
appears to develop in virtually aii patients with insulin-dependent diabetes mellitus 
(IDDM), but this is not the case for nephropathy or cardiovascular disease 
(Krolewski et. al., 1994). These differences highlight the importance of other 
systemic factors and of local conditions in the pathogenesis of the various 
complications of diabetes. 
DIABETIC NEPHROPATHY 
Over the past two decades, a rapid development has taken place 
within the field of diabetic ncphrolc ^ is clinically defined by the presence of 
persistent proteinuria (>0.5g/24 hour) in a patient with diabetes with concomitant 
retinopathy and elevated blood pressure, but without urinary tract infection, other 
renal disease, or heart failure. Diab-tic nephropathy is a relatively common 
microvascular complication of both ;" . M andnon-insulin-dependcnt (NIDDM) 
diabetes mellitus. 
Though proteinuria had been noted in patients with diabetes since 
the eighteenth century (Cotunnius et. al., 1764; Rollo J., 1798), it was not 
until the late 1830s that it was postulated that albuminuria could reflect a 
serious renal disease specific to diabetes (Bright R., 1836; Rayer P., 1940). 
The pioneer paper by Kimmelstiel and Wilson in 1936, described the 
structural lesions of diabetic nephropathy. Although the discussion maybe too 
focussed on terminology, the paper is certainly a landmark. Kimmelstiel 
studied a number of patients with striking hyaline thickening of the 
intercapillary connective tissue at times with "nodules". It became clear that 
the characteristic clinical feature was a previous history of diabetes. At the 
same time there was clear clinical evidence of renal disease or end-stage 
renal failure with widespread edema and nephrotic-range albuminuria. 
Hypertension was also found and in many cases associated with impaired 
renal function. 
Most of the patents with this syndrome probably had NIDDM. This 
clinical picture is uncommonly seen today, probably becau se we pay so 
much attention to the early detection of microalbuminuria/proteinuria and 
subsequent effective intervention. Thus edema is uncommonly seen in these 
patients because of treatment with diuretics Proteinuria can be reduced by 
antihypertensive treatment and hypertension is usually easily controlled. 
Importantly, end-stage renal failurccan be postponed. 
Epidemiology 
The epidemiology ot diabetic nephropathy has been studied 
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primarily, although not exclusively, in patients with 1DDM. The largest studies are 
from Denmark and the Joslin clinic. Although patients with NIDDM have not been 
investigated as thoroughly, major differences between ethnic groups 
have been found to exist. 
Insulin-Dependent Diabetes 
In patients with IDDM, two major cohort studies have described 
the prevalence and incidence of diabetic nephropathy, as defined by persistent 
clinical proteinuria, who developed diabetes before the age of 31 years 
(Anderson et. al., 1983, Krolewski et. al., 1985, Kofoed-Enevoldsen et. al., 1987). 
The prevalence of nephropathy increases with the durat ion of 
diabetes to a peak of 21% after 20 to 25 years, after which it declines to 
about 10% in those who had diabetes for 40 years or more. After 5 years of 
diabetes the annual incidence (the number of cases per given time) of 
nephropathy rises rapidly over the next 10 years to a peak after 15 to 17 years 
of about 3% per year. It then declines to around 1% per year in those with 
40 years or more of diabetes (Borch-Johnsen et. al., 1985). The accumulation 
of exposure to diabetes with intensity times duration is not only sufficient 
to explain the development of clinically manifest renal disease but it suggests 
that only a subset of patients are susceptible to renal complications. This 
suports the view that this complication occurs in most of the susceptible 
individuals earlier in the course of diabetes. During the first 10 years of 
diabetes, only about 4% of patients develop nephropathy. The cumulative inci-
dence increases thereafter to a plateau after about 25 years of diabetes. 
The proportion of patients with Juvenile diabetes developing nephropathy 
u 
has changed over the years (Krolewski et. al., 1985, Kofoed-Enevoldsen et. al., 
1987). In cohort of patients diagnosed before 1942, the cumulative risk 
upto 25 to 30 years of duration of diabetes was approximately 41%, but in 
patients diagnosed after 1949, it declined to around 25%. Although the 
reason(s) for the lower frequency of diabetic nephropathy is not entirely clear, 
the cohort differences may be related to changes in diabetes care and control, 
to more intensive and early treatment of concomitant conditions such as 
hypertension, or, less likely, to dietary changes. 
The difference in the incidence of renal disease in males (46%) and 
females(32%) diabetic patients followed for 40 years or more, is also found 
in subjects without diabetes(Finn et. al., 1979, Pasternack et. al., 1985). It is of 
interest that some authors have also reported a male preponderance in the devel-
opment of proliferative diabetic retinopathy (Danielsen et. al., 1983, Klein 
et. al., 1986). 
Age at diagnosis significantly influences the risk of nephropathy 
and nephropathy develops more slowly in individuals with onset of diabetes 
before the age of 10 years than in those with diagnosis after puberty (Krolewski, 
1985). The highest cumulative incidence of 44% is seen in subjects who developed 
diabetes between 11 and 20 years of age (Kofoed-Enavoldsen et. al., 1987), while 
in those with a diagnosis after the age of 20, the cumulative incidence of nephropathy 
is about 35%. Current age has been found by some authors 
(Krolewski, et. al., 1985) but not by others (Kofoed-Enevoldsen et. al., 1987) to 
influence the incidence of proteinuria, with a maximal risk in the age 
interval 18 to 35 years and a rapid decline in incidence after age 35 years 
regardless of duration of diabetes (Derby et. al., 1988). The discrepancy in 
findings may be related in part to the different age groups of the cohort 
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Studied. 
It has long been suspected that a genetic predisposition to hyperten-
sion may exist. Diabetic nephropathy develops in less than half of all patients 
with IDDM and there is a huge over-lap with respect to metabolic control in 
those developing nephropathy and those not developing nephropathy. Thus genetic 
factors may be involved. This hypothesis was examined by investigating the 
concordance rate for diabetic nephropathy in two sets of families in which both 
probands and siblings had diabetes mellitus. In the probands without evidence of 
nephropathy, nephropathy was quite rare in the s ibl ings. On the 
other hand, in the siblings of probands with diabetic nephropathy, 82% had 
evidence of nephropathy, including 12 patients with end-stage renal failure 
(Seaquist et. al., 1989). This observation is consistent with the hypothesis 
that heredity helps to determine susceptibility to diabetic nephropathy. It 
is possible that environmental factors shared by siblings could be involved 
and this is suggested in a new study indicating families with diabetic 
nephropathy show poor glycaemic control. 
Diabetic nephropathy occurs with great prevalence among Pima 
Indians in Arizona. This Indian tribe is an example of the very high prevalence of 
diabetes amongst the native Americans, but is also seen in Mexican-Americans. 
Pettitt and coworkers, 1990 studied the occurrence of renal disease by 
measuring serum creatinine and urine protein in the diabetic members of 
316 Pima families with NIDDM in two successive generations. After 
adjustment for a number of risk factors, it was found that proteinuria was 
highly dependent upon family history of proteinuria. If both parents had proteinuria, 
the risk of proteinuria in the individual was about three times 
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higher than if none of the parents had proteinuria. Indeed, proteinuria and 
high serum creatinine in diabetic families suggest that susceptibility to renal 
disease may be inherited independently of diabetes. However, sharing of 
environmental risk factors may still be involved. 
The development of end-stage renal failure and its associated 
mortality closely conform to the occurence of persistent proteinuria (Krolewski 
et. al., 1985); 25% develop end-stage renal failure within 6 years, and 75% within 
15 years of onset of proteinuria. The median time interval between onset of 
persistent proteinuria and the development of end-stage renal failure was 
14 years in the group of subjects with the onset of diabetes before age 
12 years and was 9 \ ears in those with onset of diabetes between the ages of 12 and 
20 years (Krolewski, et. al., 1985). The range of survival after the onset of 
persistent proteinuria is wide between 1 and 24 years. Median survival has 
been reported to be around 7 to 10 years (Anderson et. al., 1983, Krolewski 
et. al., 1985). 
The development of persistent proteinuria in patients with IDDM 
increases early mortality caused by cardiovascular disease by approximately 
ninefold (Borch-Johnsen et. al., 1987; Jensen et. al., 1987). The risk of 
developing coronary artery disease is estimated to be 15 times higher in 
those with proteinuria than in those without proteinuria (Krolewski et. al., 1987) 
and its cumulative incidence 6 years after onset of proteinuria is eight 
times higher than in matched controls without renal involvement (Jensen 
et. al., 1987, Table 1). Whatever the cause, mortality from all by ago 
45 years decreases in IDDM patients with proteinuria has been reported 
to be 20 to 40 times higher than that in patients without proteinuria, who 
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experience a relative mortality only double that of the non-diabetic 
Table-1. Cumulative incidence of Coronary Heart Disease in patients 
with Insulin-Dependent Diabetes with and without Proteinuria 
Cumulative incidence(%) at indicated 
year after proteinuria. 
Group 
Patients with proteinuria 
Patients without 
proteinuria 
2 
10 
2 
4 
25 
5 
6 
40* 
5* 
Table is adopted from Jensen et. al.,, 1987 
* P<0.001: Patients with proteinuria at 6 years vs. patients without 
proteinuria at 6 years. 
population (Borch-Johnsen et. al., 1985). Recent studies suggest that more 
effective antihypertensive treatment during the past decade has significantly 
improved the prognosis in patients with diabetic nephropathy. The 10-year 
survival rate after onset of persistent proteinuria has risen from 30 to 50% 
(Andersen et. al., 1983, Krolewski et. al., 1985) to about 80% (Parving et. a!., 
1989; Mathiesen et. al., 1989, Fig.l). 
Non-Insulin-Dependent Diabetes 
The overall prevalence of proteinuria (>500 mg/24 hour) has been 
reported to be approximately 16% in one study of European patients with 
diabetes diagnosed after the age of 40 years (Fabre et. al., 1982). The lower 
prevalences of 12 to 14%, with a higher prevalence in men (19%) than in 
women (4%) have been reported by other studies(Klein et. al., 1988, WHO, 
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1985). The prevalence of proteinuria increases steadily with duration of 
diabetes- from 7 to 10% in patients with diabetes diagnosed less than 5 years 
previously to 20 to 35% in patients with diabetes diagnosed more than 20 
to 25 years earlier (Fabre et. al., 1982, Klein, et. al., 1988). In non-European 
patients with NIDDM, the lowest prevalence of proteinuria (2.4%) has been 
reported in patients in Hong Kong WHO, 1985), but prevalences higher 
than in European patients have been found in American Indians (WHO, 
study of vascular disease in diabetes, 1985; Rate et. al., 1983; Nelson et. al., 
1989), Mexican Americans (Haffner et. al., 1989), African Americans (Cowie 
et. al., 1989), Japanese (WHO, 1985), Nauruan from central pacific islands 
(Samanta et. al., 1986), in whom an increased prevalence of microalbuminuria 
has also been described (Allawi et. al., 1988). 
A male preponderance in the prevalence of proteinuria has been 
reported by some authors (Ballard et. a!., 1988). Both blood glucose control 
and level of arterial pressure have been related to prevalence of proteinuria 
in a number of ethnic groups. Sixty-two percent of European patients with NIDDM 
maintain normal protein excretion after 16 years of diabetes. Those 
who develop proteinuria have a higher prevalence of hypertension before 
onset of persistent proteinuria than i a those who do not (Hasslacher et. al., 
1988). These findings suggest that cumulative exposure to diabetes and to 
raised arterial pressure are both important determinants of renal involvement 
in NIDDM. The incidence rate of nephropathy, as measured by persistent 
proteinuria, rises with duration of diabetes, with a cumulative risk of 
proteinuria of about 50% after 20 years of diabetes in patients with NIDDM 
of Japanese (Sasaki et. al., 1986) and of Pima Indians (Kunzelman et. al., 1989), 
16 
25% in patients with NIDDM of European origin in a population-based 
study in the United States (Ballard et. al., 1988) and 57% in European subjects 
after 25 years of diabetes (Hasslacher et. al., 1989). Recently it has been 
observed that in Pima Indians an elevation in blood pressure before the 
onset of diabetes predicts abnormal albuminuria (Knowler et. al., 1988) and 
that the risk, of development of diabetic nephropathy in the offspring of a 
diabetic parent is markedly increased when the parent also has diabetic renal 
disease (Pettitt et. al., 1990). 
Progression to end-stage renal failure in proteinuric patients with 
NIDDM is variable. A cumulative risk of chronic renal failure of 12% after 15 
years of diabetes who had persistent proteinuria at the time of diagnosis has 
been described. In those patients who develop proteinuria after the diagnosis 
of diabetes, the cumulative risk was 17%, 15 years after the onset of 
persistent proteinuria (Humphrey et. a'., 1989). In another study of 
European patients, followed for a median duration of 20 years, the cumulative 
risk of renal failure (diagnosed by a serum creatinine level of > 124 u mol/L) 
3 and 5 years after onset of persistent proteinuria was even higher, at 41% 
and 63%, respectively, but this may reflect the less stringent criterion 
for renal failure (Hasslacher et. al., 1989). The discrepancy between frequency 
of proteinuria and end-stage renal failure may arise for different reasons. 
This could be because of associated cardiovascular disease and may not be 
considered for renal replacement therapy (Joint working Party on Diabetic 
renal failure, 1989) or may die before they reach end-stage renal failure. 
Proteinuria of non-diabetic origin, which occurs in close to 30% of 
proteinuric patients with NIDDM (Parvinget.al., 1990,GrenfeU et. al., 1988) may 
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also contribute to this disparity. 
In a prospective study of a cohort of 500 subjects with NIDDM 
10-year survival was significantly poorer, at about 30% among patients with 
elevated urinary albumin excretion rates ranging from microalbuminuria to 
clinical proteinuria, as compared with the 10-year survival of 55% among 
patients with normal albumin excretion rates. About 58% deaths were due 
to cardiovascular causes, only 3% ascribed to uraemia (Schmitz et. al., 1988). 
Similar results were obtained in a 10 to 12 year prospective study of middle-
aged patients with diabetes of the London Cohort of the WHO multicenter 
study of vascular disease in diabetic patients. Age-adjusted deaths were 
significantly greater in patients with NIDDM who had proteinuria and/or 
hypertension (Morrish et. al., 1990). These data are in agreement with the 
previous reports from prospective studies of European patients with NIDDM, 
in whom microalbuminuria markedly increased the risk of cardiovascular 
death (Jarret et. al., 1984, Mogensen 1984). 
The incidence of end-stage renal failure is strongly associated with 
the presence of proteinuria in non-European ethnic groups with NIDDM. 
In diabetic Pima Indians, the incidence of end-stage renal failure increases 
with duration of diabetes and after 20 years, the cumulative risk of 
this complication reaches 15% (Nelson et. al., 1988). An excess incidence of 
ESRD, compared with the incidence in European NIDDM patients, has also 
been reported for Mexican Americans (Mexican-American/American white 
ratio ~ 6) Pugh et. al., 1988 and in African-Americans with diabetes 
(Cowie et. al., 1989; Rostand et. al., 1982). An excess of Afro-Caribbean and 
Asian patients has been found among NIDDM patients treated for ESRD, in the 
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United Kingdom (Grenfell et. al., 1988), and its incidence has been reported 
to be higher in patients with NIDDM in African countries (Abdullah MS., 
1978,Adetuyibi, 1976). 
In diabetic Pima Indians, proteinuria confers a 3.5 fold higher risk 
of premature mortality and to concomitant presence of arterial hypertension 
increases this relative risk to 7.1(Nelson et. al., 1988). The mortality rate for 
the diabetic Pima Indians without proteinuria is similar to that for the non-diabetic 
subjects of the excess mortality associated with NIDDM in this 
population, 97% is found in patients with proteinuria. Sixteen percent of 
deaths were ascribed to Uremia, while 22% were due to cardiovascular 
disease. The mortality figures are slightly higher than the two to three fold 
excess in early mortality observed in the European patients with NIDDM 
with proteinuria (Schmitz et. al., 1988, Morrish et. al., 1990). 
MECHANISM OF PROTEINURIA IN DIABETIC RENAL DISEASE 
In normal humans, very little protein is lost in the urine because the 
glomerular capillary wall imposes an efficient barrier to passage of 
macromolecules, excluding them from Bowman's space by both size and 
charge. The glomerular capillary wall, composed of the fenestrated endothelial 
cells, basement membrane, and visceral epithelial cells with interdigitating 
podocytes, has a permeability to macromolecules that is amongst the lowest 
in circulation. Leakiness of the glomerular capillary wall to proteins is the 
first sign of glomerular injury in diabetes and a reliable predictor of 
eventual renal failure in this disorder. 
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The permeability of the normal glomerular capillary wall to 
macromolecules 
The glomerular capillary wall principally excludes macromolecules 
from Bowman's space by molecules' size. Molecules the size of inulin or 
smaller penetrate the capillary wall as freely as water, but permeability 
decreases progressively with size, becoming very low as size nears that of 
serum albumin. Two methods have been used to assess the size-selective 
properties of the glomerular capillary wall. The first method requires 
analysis of fluid samples collected from Bowman's space by micropuncture 
in animals (Oken et. al., 1981). The Bowman's space to plasma concentration ratio 
for a given protein then provides the fractional filtration or "Sieving 
coefficient" for that protein. The second method measures the urinary 
clearance rates for intravenously infused test macromolecules (Deen 
et. al., 1983). This method avoids the difficulties encountered in analysis of 
small amounts of protein in tubule fluid samples, and can moreover be 
employed in human studies . The fractional c learance of a test 
macromolecule^ M) is defined as the clearance of M divided by the 
glomerular filtration rate (GFR). When inulin is used to measure the GFR, the 
fractional clearance of a test macromolecule can be expressed as: 
Fractional clearance of M = (U/P)M / (U/P) in 
where (U/P)M and (U/P)in are the urine-to-plasma concentration ratios for the 
macromolecule M and for inulin. If, like inulin, the test macromolecule is 
neither reabsorbed nor secreted by the tubules, its fractional clearance will be 
equal to its fractional filtration by the glomerulus: 
Fractional Clearance of M = QM 
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The test substances most frequently used to probe glomerular 
permeability to the macromolecules have been the nonprotein polymers dextran 
and polyvinylpyrrolidone (Deen et. al., 1983). These substances are available 
in a broad range of molecular sizes, do not appear to be secreted or 
reabsorbed by renal tubules, and can be infused into humans. 
In addition to size, the glomerular capillary wall also excludes 
macromolecules from Bowman's space by molecular charge. The charge-
selective properties of the glomerular capillary wall have been most 
clearly demonstrated in animals, in which the clearances of charged and 
neutral test macromolecules can be directly compared. Bohrer et. al., 1978 
showed that in normal rats t.ie clearance of anionic dextran sulfate 
molecules is 10 to 50-fold lower than the clearance of neutral dextran 
molecules over the size range 26A° to 42A°. Further studies have shown that 
the capillary wall loses its ability to discriminate against anionic dextrans in 
rats, with glomerular disease (Bennett et. al., 1976; Bohrer et. al., 1977; 
Olson et. al., 1981). These results can be explained on the assumption that 
the normal glomerular capillary wall carried a fixed negative charge that is 
reduced by glomerular disease (Deen et. al., 1981). Unfortunately, ethical 
considerations so far have prevented administration of dextran sulfate to 
humans. Presumably, however the glomerular capillary wall discriminates 
against anionic macromolecules in humans as it does in rats. Glomerular 
charge-selectivity is thought to account in part for the finding that the 
clearance of albumin is lower than the clearance of dextran of the same size. 
Moreover, it is widely assumed that loss of capillary wall anionic charge 
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contributes to proteinuria in both human and experimental glomerular disease. 
In addition to the intrinsic properties of the glomerular capillary wall, 
including size and charge-select ivi ty, the glomerular fi l tration of 
macromolecules is determined by the hemodynamic factors which govern 
the GFR (Deen et. al., 1983). Thus proteinuria can be altered by hemodynamic 
events, such as changes in volume or blood pressure, independent of any 
change in capillary wall structure. The influence on macromolecule filtration 
of glomerular haemodynamic factors, which include the glomerular plasma 
flow rate, the transcapillary hydraulic pressure and the arterial piasma 
protein concentration, is complex and difficult to predict. In general the 
maneuvers that increase the filtration fraction while GFR remains constant 
may be expected to increase the glomerular filtration of macromolecules 
the size of albumin. 
The development of proteinuria in diabetic renal disease Early 
"Functional" Proteinuria 
During the first decade of diabetes, values for urinary albumin 
e5«3retion rate (UAER) usually remain normal, averaging <10 mg/d. There are, 
however, atleast two circumstances in which transient increase in UAER may 
be observed m patients with early diabetes. First, elevation of UAER may 
be observed during episodes of poor metabolic control (Parving, et. al., 1976). 
Values for UAER in this setting usually remain <50 mg/d, but higher values 
have sometimes been recorded. Second, exercise may increase UAER to values as 
high as 50 mg/d in diabetic patients whose resting values for UAER are 
normal (Mogensen et. al., 1979, Vittinghus et. al., 1982). In both circumstances, 
urinary excretion rates for P2 microglobulin, a small, macromolecule 
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whose excretion is controlled largely by tubule reabsorption. remain 
unaltered. Albuminuria thus presumably reflects increased glomerular 
filtration rather than decreased tubular reabsorption of albumin. 
Poor metabolic control has been shown to increase the albumin 
excretion rate in patients with diabetes of only a few months duration, in 
whom defects in glomerular capillary wall structure presumably have not 
yet developed (Parving 1976). Albumin excretion rates are rapidly reduced follow-
ing improvement in metabolic control and cessation of exercise , 
further suggesting that increased albumin filtration in these circumstances 
cannot be attributed to fixed defects in glomerular size- or charge-selectivity 
(Parving et. al., 1976; Vittinghus et. al., 1982). It has also been shown that 
angiotensin II can increase urinary albumin excretion by causing a transient defect 
in glomerular size-selectivity (Bohrer 1977; Yoshiqka. 1987). Altered glomerular 
hemodynamic function and impairment of glomerular size-
selectivity induced by angiotensin II have been considered to cause reversible 
albuminuria in patients with heart failure (Carrie et. al., 1980). Similar 
hemodynamic and humoral changes may cause transient albuminuria durii g 
poor metabolic control and during exercise early in the course of diabetes. 
In patients with diabetes of several years duration, transient 
increase in UAER may result from the combination of altered glomerular 
hemodynamic function with early changes in glomerular capillary wall 
structure. It is not yet known, however, whether exercise induced albuminuria, like 
resting microalbuminuria, predicts the development of clinical nephropathy in 
diabetes. 
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MICROALBUMINURIA 
In clinical practice, the diagnosis of diabetic nephropathy has usually 
been established by the finding of dipstix positive proteinuria. However, 
such methods give positive results only when urinary albumin concentration 
and excretion is increased from normal by a factor of approximately 20 times, 
representing albumin excretion rate of approximately 500 mg/day. However, 
recent studies have emphasized the value of identifying patients with 
microalbuminuria, usually defined as having albumin excretion rates in 
the range of 30 to 300 mg/d. Long-term studies have shown that albumin excretion 
in such pat ients increases over several years to rates in excess 
of 500 mg/d. Development of this clinical level of albuminuria in turn 
reliably predicts the ultimate loss of kidney function in diabetic patients. 
The small defect in glomerular barrier function which causes 
microalbuminuria must therefore be regarded as the first sign of a 
pathological process that leads inexorably to renal failure. 
The permselectivity defect(s) responsible for microalbuminuria 
have been difficult to identify because the macromolecule excretion rates, 
though abnormal, are still very low. It is important to note that excretion of 
proteins other than albumin is increased in patients with microalbuminuria. Em-
phasis has been placed on albumin excretion because albumin is the 
predominant, and therefore the most easily measurable protein in the urine 
and plasma. When measurements have been made, however, diabetic 
patients with values for UAER of 30 to 300 mg/d have been found also to 
exhibit increased excretion of immunoglobulin G (Viberti et. al., 1983; 
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Deckert et. al., 1988). The finding of increased quantities of this large protein 
in the urine implies that a defect in the glomerular size-seis:tivity contributes 
to proteinuria in patients with microalbuminuria. More rigorous proof that a 
defect in size selectivity contributes to early proteinuria in diabetes has 
been provided by a study showing that glomerular permeability to dextran 
molecules with radii 50 to 60A° is increased in type II diabetic patients 
with albumin excretion rates averaging <50 mg/d (Loon et. al., 1989). Given 
that a charge selectivity defect accompanies the size- selectivity defect in 
diabetic patients with heavier proteinuria. It seems likely that a charge-
selectivity defect also accompanies the size-selectivity defect in diabetic 
patients with microalbuminuria. Attempts to identify a charge-selective 
defect early in the course of diabetic nephropathy by comparing clearance 
values for Ig G molecules with differeiil isoelectric points have yielded 
inconclusive results (Deckert et. al., 1988, Loon et. al., 1989, Nakamura et. a!., 
1988). Recently it has been reported that the prevalence of sodium 
sensitivity is high in IDDM and that the sodium sensitivity is found in the 
absence of nephropathy as indicated by albuminuria (Strojek et. al., 1995). 
Clinical Proteinuria 
The mechanisms responsible for proteinuria in diabetic patients 
with clinical nephropathy have been extensively investigated by Nakamura 
and Meyers et. al., 1988, Friedman et al., 1983 and Tomlanovich et. aL, 1987. 
They have identified a size selectivity defect, reflected by enhanced clearance 
of dextrans with radii from 50 to 60A° in diabetic patients with protein 
excretion from 300 mg/d to more than 10 g/d. To assess to magnitude of this 
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size-selective defect, Deen et. al., 1985 have used a "heteroporous" model of 
the glomerular capillary wall. This model assumes that in injured as in 
normal glomeruli, the major portion of the capillary wall is perforated 
by cylindrical pores of radius. This model further assumes that 
smaller portion of the capillary wall is permeated by "shunt" pores so large 
that they exhibit no size- selectivity. The portion of the capillary wall 
permeated by shunt pores as opposed to normal pores, can be determined from 
dextran clearance profiles. This parameter provides quantitative measure of the 
magnitude of the size-selectivity defect in injured glomeruli.. 
Two important conclusions have so far emerged from the theoretical 
analysis of dextran clearance studies performed by Friedman et. al., 1983 and 
Tomlanovich et. al., 1987 in patients with diabetic renal disease. The finding 
that urinary protein excretion rates were maintained as the GFR decreased 
clearly implies that fractional protein excretion rates increased over the 
course of the study. Dextran sieving studies showed that this increase in fractional 
protein excretion was caused by a progressive impairment of 
glomerular-s ize-select ivi ty , reflected by an increase in the shunt 
parameter as renal disease advanced. It should be noted that proteinuria 
has also been shown to remain at high levels as GFR declines in patients 
with other glomerular disease (Brand et. al., 1968) Mc Morrow et. al., 1982, 
Brown (et. al., 1978). Experimental studies suggest that these findings may 
reflect aggravation of glomerular barrier injury associated with hypertrophy 
of remnant glomeruli when nephrons are lost in the setting of established 
nephrosis (Meyer et. al., 1988). 
The heteroporous model provides an incomplete description of 
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glomerular permeability to macromolecules in diabetic renal disease. If 
circulating macromolecules escaped injured glomerular clearances of 
various proteins would be equal. Multiple studies have shown, however 
that values for the fractional clearance of albumin are several fold greater 
than values for the fractional clearance of Ig G in patients, with diabetic nephropathy 
(Viberti et. al . , 1983, Deckert et. al . , 1988, Loon et. a!., 1989, 
Nakamura et. al., 1988, Friedman et. al., 1983, Tomlanovich et. a!., 1987). The 
likely explanation is that impairment of glome ular charge-selectivity 
accompanies impairment of glomerular size-selectivity in diabetic renal 
disease, (so that glomerular size-selectivity in diabetic renal disease) so 
that glomerular permeability to albumin is increased relatively more than 
glomerular permeability to Ig G. 
PROTEINURIA IN TYPE II DIABETES 
Most of the studies described have been performed in patients with 
Type I diabetes. Available studies suggest, however, that the pattern of 
proteinuria is similar in Type I and Type II diabetes (Mogensen 1984; 
Nelson et. al., 1988; Ballard et. al., 1988; Kunzelman et. al., 1989; Ordonez et. al., 
1989). One difference between the two conditions is that patients with 
type II diabetes may exhibit dipstis positive proteinuria at the time when diabetes 
is diagnosed (Ballard et. al., 1988; Fabre et. al., 1982; Unsitupa et a!., 
1987). Insulin resistance and hypertension may precipitate glomerular injury 
before development of overt hyperglycaemia in these patients (Rosenmann 
et. al., 1971; Cohen et. al., 1971; Modan et. al., 1985; Ferrannini et. a!., 1987). 
27 
CLINICAL COURSE AND NATURAL HISTORY 
The natural history of renal involvement has been better defined in 
IDDM than in NIDDM, partly because the usual relatively acute onset of 
diabetes in the former allows for a more precise timing of observed clinical 
and physiologic events. 
Early Phase 
A clinically silent phase of variable duration occurs after diagnosis 
of diabetes and during this period, important abnormalities of renal function 
and structure takes place. GFR is found to be elevated on average by 20 to 
40% above that of age-matched normal subjects both in adults and children 
with IDDM (Cambier 1934, Fiaschi 1952, Stalder 1959, Ditzel 1967, 
Mogensen 1971). Data for NIDDM are controversial with some groups 
reporting normal and others supranormal GFR values(Schmitz 1989. 
Palmisano 1989,Vora 1990, Loon 1990). Approximately 25% of patients with 
IDDM have a GFR exceeding the upper limit of normal range (Wiseman 
et. al., 1984). Hyperfiltration is related to the degree of control of blood 
glucose, atleast within the range of normal levels to moderate 
hyperglycaemia (i.e. to 14 mmol/L), whereas higher blood glucose values 
tend to be associated with normal or low GFR (Wiseman 1984). Intensified insulin 
treatment and good metabolic control bring the GFR towards normal 
levels after a period of weeks to months in both IDDM (Christiansen 
et al., 1982, Wiseman et al., 1985) and NIDDM (Schmitz et. al., 1989). Renal 
plasma flow (RPF) has been reported to be elevated, normal or reduced in 
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IDDM (Mogensen et al., 1971, Christiansen et. al., 1981,DitzeI et. al., 1972) 
although more recent work shows an elevation of RPF ranging between 9 and 
14 % (Christiansen, 1984). 
The increased GFR and RPF are accompanied by an increase in 
kidney size of approximately 20% and a good correlation between GFR and kidney 
volume has been described in patients with IDDM (Christiansen et. al., 1981; 
Mogensen, 1973; Puig et. al., 1981). Approximately 40% of patients with 
IDDM have kidneys that are larger than normal. A large kidney is a 
prerequisite for the occurence of GFR above the upper limit of the 
normal range, but normal GFRs can be found in patients with large 
kidneys (Wiseman et. al., 1983). The relationship of kidney size to glycaemic 
control is less clear-cut than that of GFR. In newly diagnosed patients with 
IDDM (Mogensen, et. al., 1975) and NIDDM (Schmitz, et. al., 1989) 3 months 
of insulin treatment has been claimed to reduce kidney size. Some authors 
have described a relationship between blood glucose control and kidney 
volume, variation of HbA,C accounting for 33% of variation in kidney 
volume (Feldt-Rasmussen, et. al., 1991). In longer-term, treatment with an 
intensified insulin regimen for periods of upto 1 year failed to decrease the 
size of the enlarged kidney in spite of a reduction in GFR in 
normoalbuminuric patient with IDDM (Christiansen, et. al., 1982, Wiseman 
et. al., 1985,Christiansen, 1986). It is not known why renal enlargement 
becomes irreversible and this may have prognostic implications for the 
development of clinically ignificant renal damage (Kleinman, et. al., 1988). 
A positive correlation between initial hyperfiltration and 
subsequent increase in albuminuria and development of cl inical 
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nephropathy was described in two retrospective studies (Mogensen et. al., 
1984; Mogensen et. al., 1986) but these findings were not confirmed by a 
more recent study spanning an observation period of 18 years (Lervang 
1988). The 5-year results of an ongoing prospective case-controlled 
study of patients with IDDM with and without hyperfiltration (Jones et. a!., 
1991) suggest that diabetics with hyperfiltration, although showing, a faster 
rate of GFR decline do not show an increased frequency of rising 
albuminuria or blood pressure. 
A significant increase in albumin excretion rate (AER) to three 
to four times above the normal level was first demonstrated in NIDDM 
patients that was newly detected in a population survey (Keen, et. a!., 1969). 
Young subjects with newly diagnosed IDDM or subjects with short-term 
diabetes in poor control often demonstrate an elevated AER (Mogensen 
et. al., 1971, Parvinget. al., 1976; Mogensen et. al., 1976). Subclinical elevation 
in rates of both albumin and Ig G excretion also are found in patients with long-
term IDDM (Viberti et. al., 1982). These abnormal although subclinical 
increase in AER have been termed microalbuminuria. Albumin excretion in healthy 
individuals ranges between 1.5 and 20 ug/min, with a geometric mean 
6.5 ug/min. These levels have been termed normoalbuminuria. The wide use 
of chemical reagent "dipstix" has led to the definition of persistent or 
clinical proteinuria in patients whose urine is positive in these tests. Such 
patients generally have AERs in excess of 200 ug/min. Microalbuminuria thus 
defines the wide subclinical range of albumin hypersecretion ranging 
between 20 and 200 ug/min. (Mogensen, 1986). 
AER both in normal individuals and diabetic patients tends to be 
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about 25% higher during the day than during the night and exhibits an average 
day to day variation of about 40% (Mogensen, 1971, Feldt-Rasmussen et. al., 
1984; Mathiesen et. al., 1984; Rowe et. al., 1985; Cohen et. al., 1987; Chachati 
1987). An important practical implication of this variability is that accurate 
classification of AERs should depend on measurements for atleast three 
collections over a 6-month period. The prevalence of microalbuminuria in 
IDDM has been reported to range from 5 to 37% in different population-
based and diabetes cl inic-based studies (Mathiesen et. a l . . 1986, 
Microalbuminuria collaborative study Group UK, 1995, Gardete et. al., 1987, 
Gatling et. al., 1988, Parving et. al., 1988). The differences in prevalence are 
most likely due to patient selection. No correlation is found with age, but 
there is a male preponderance among microalbumireuric patients with 
IDDM, who also tend to have an early onset and longer duration of diabetes 
than normoalbum.inurie patients (Parving 1988; Marshall 1989). Persistent 
elevations in AER are exceptional in the first 5-years of diabetes 
(Microalbuminuria Collaborative study Group UK, 1995, Marshall 1989) and 
microalbuminuria has not been detected in children younger than 15 years 
of age (Mathiesen, et. al., 1986). The phase of persistent microalbuminuria 
has been termed incipient nephropathy by some authors (Mogensen et. a!., 
1983). AER is influenced by glycaemic control and correction of 
hyperglycaemia can reduce microalbuminuria, in long-term as well as short-
term IDDM (Parving et. al., 1976; Mogensen, 1976; Viberti et. al.. 1982; 
Viberti et. al., 1979). Moderately strenuous exercise is also capable of 
provoking an exaggerated rise in AER in patients with diabetes whose 
resting values are normal (Mogensen, et. al., 1975, Viberti, et. al., 1978). 
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The prevalences of microalbuminuria in NIDDM have been 
reported ' between 8% and 46% in Europeans (Fabre et. al., 1982, Schmitz 
et. al., 1988, Catling et. al., 1988, Marshall et. al., 1989,Damsgaard et. al., 1986) 
and 47% in Pima Indians(Nelson 1989). No correlation is found between 
microalbuminuria and sex, but significiant positive associations are found 
between microalbuminuria and diastolic blood pressure and resting heart rate 
(Allawiet. al., 1990). 
Five longitudinal st dies of cohorts of IDDM patients, have demons-
trated the prognostic significance of micioalbuminuria for development of 
persistent proteinuria (Mogensen et. al., 1984; Mathiensen et. al., 1984; 
Viberti et. al., 1982; Parving et. al., 1982; Jerums et. al., 1987). All of them 
have suggested the existence of a threshold of AER above which the risk 
of progression to clinical nephropathy increases by about twentyfold. The 
differences in methods of urine collections and length of follow-up 
probably is responsible for the different risk levels of AER(Table II) . 
Microproteinuria is more like a sign of early disease and unlikely 
to be a marker of susceptibility to the development of clinical nephropathy, 
as it is undetectable in the first 5 years of diabetes (microalbuminuria 
coUaporative study Group, UK, 1995).. 
The prognostic value of microalbuminuria have also been examined 
in cohorts of NIDDM patients in three retrospective studies (Schmitz et. al., 
1988, Jarrett et. al., 1984, Mogensen et. al., 1984). Over an interval of 10 to 
14 years, they have all shown an increased risk of cardiovascular death in 
these patients. A recent prospective study of 3 years duration has confirmed 
the greater incidence of cardiovascular events in patients with NIDDM 
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with microalbuminuria (Mattock et. al., 1992). 
Table-II. Predictive value of AER for persistent clinical proteinuria in 
patients with NIDDM. 
No. of Baseline Follow-up Type of Predictive 
subjects AER (Yr.) collection value 
(Hg/min.) 
Viberti et. al.,1982 
Parvinget. al.,1982 
Mathiesen et. al.,1984 
Mogensen and 
Christensen,1984 
Jerums et. al.„1987 
63 
23 
71 
43 
53 
>30 
>28 
>70 
>15 
>30 
14 
6 
10 
10 
8 
Overnight 88%(7/8) 
24 hr 63%(5/8) 
24 hr 100%(7/7) 
short-term 86%(12/14) 
24hr 25% (1/4) 
Late Phase: Clinical Nephropathy 
The clinical phase of diabetic nephropathy is signalled by the 
appearance of persistent proteinuria (Total protein excretion of >0.5 g/day), 
which corresponds to an AER greater than 200 ^ig/min. (i.e. 300 mg/day). A 
phase of intermittent dipstick positivity of urine for protein precedes 
persistent proteinuria (Ireland et. al., 1982) but likely this corresponds to 
the late phases of high microalbuminuria, with values intermittently breaking 
the clinical threshold (Jerums et. al., 1987, Bending et. al., 1986). There is a 
progressive decline of the GFR to end-stage renal failure in those subjects in 
whom persistent proteinuria develops (Mogensen, 1976, Jones et. al., 
1979, Parving et. al., 1981, Viberti et. al., 1983). Whether the fall in GFR 
starts at the time of or after the appearance of the microalbuminuric phase 
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is a matter for debate (Bending et. al., 1986, Feldt-Rasmussen et. al., 1986). 
Adequacy of blood glucose control has only a limited impact on 
progression (Viberti et. al., 1983, Hasslacher et. al., 1985) even though some, 
but not all, authors have reported a correlat ion between levels of 
glycosylated hemoglobin and rate of fall of GFR (Nyberg et. al., 1987, 
Viberti et al.,1987). In a recent study, intensive therapy with improved 
glycaemic control for three years had no impact on the progression of 
albuminuria in insulin-dependent diabetic patients with microalbuminuria 
(Microalbuminuria Collaborative study Group (UK, 1995). The level of 
diastolic blood pressure has been found to be correlated with the rate of progres-
sion of establ ished diabetic nephropathy, and serum creat inine 
concentrations have been reported to rise sooner in those proteinuric 
patients with the higher blood pressure levels (Mogensen, 1976, Hasslacher 
et. al., 1985, Laffel et. al., 1987). The failure of other authors (Jones et. al., 
1979, Parving et. al., 1981,Viberti et. al., 1983) to confirm the relationship 
with blood pressure may result from the current more widespread treatment 
of mild hypertension in these patients. In evaluation of the rate and 
magnitude of all of GFR, caution must be applied when serum creatinine or 
creatinine clearance is used as an index of glomerular function (Walser 
et. al., 1988). Because of the asymptomatic relationship between serum 
creatinine and GFR, there may be no rise in serum creatinine level until 
more than 50% of the GFR has been lost. A linear decline in inverse creatinine 
is not seen for serum creatinine concentrations below 200 |i mol/L (Jones 
et. al., 1979). Moreover, the use of creatinine clearance tends to overestimate 
GFR because of the enhanced tubular secretion of creatinine that takes 
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place in advanced renal failure (Shemesh et al 1985). 
The end-stage renal failure occured on average 7 years after the onset 
of persistent proteinuria in the past, however, in recent years, this interval 
has probably more than doubled with early, more intensive antihypertensive 
treatment (Parving et. al., 1989, Mathiesen et. al., 1989) and early restriction of 
dietary protein (Walker et. al., 1989, Zeller et. al., 1991). In diabetic patients 
with established nephropathy, arterial pressure is almost invariably elevated. 
A small proportion ( 25%) of patients may still have blood pressure within 
the so-called normal range at the onset of persistent proteinuria, although it may 
have risen within the normal range from previous lower levels before the 
onset of proteinuria (Mathiesen et. al., 1984, Wiseman et. al., 1984, Jensen 
et. al., 1987). Virtually all patients become hypertensive with progression to 
renal insufficiency (Parving et. al., 1989, Ireland et. al., 1982, Hasslacher et. a!., 
1985). Several studies suggest that the excess of arterial hypertension 
described in IDDM patients is almost entirely accounted for by patients with 
persistent proteinuria (Hasslacher et. al., 1985, Keen et. al., 1975, Drury, 1983). 
Patients with long-term IDDM without proteinuria have blood pressure that are 
indeed lower than those of age-matched controls (Borch Johnsen et. al., 1985). 
The degree of proteinuria in patients with diabetes is usually in the 
subnephrotic range, but heavy protein excretion and nephrotic syndrome 
may occur and this has been related to a poorer renal outcome (Watkins 
et. al., 1972). The level of proteinuria is related to the degree of severity 
of glomerular lesions, but glomerular histologic damage has been 
reported in patients without proteinuria (Watkins et. al., 1972, Thomson, 
1965). 
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End-stage Renal Failure 
A number of other complications compound the development of 
uraemia in patients with diabetes. In the absence of hypoalbuminemia, 
fluid retention and edema occur relatively early in the development of 
renal failure (Taft et. al. 1990). The variable contributions, in older patients 
of cardiac insufficiency and of vasomotor defects secondary to neuropathy 
and peripheral vascular disease are well recognised (Rifkin et. al., 1948, 
Bell, 1953, Gellman et. al., 1959). Depressed renal function further 
compromises disposal of water and solutes, and impairs osmotic diuresis, 
especially in the face of rapid compartmental shifts of fluid secondary to varia-
tions in glycaemia (Axelrod, 1975). Hyperkalemia developing as a result 
of hyporeninemic hypoaldosteronism is common in pa t ients with 
advanced diabetic nephropathy (DeFronzo et. al., 1980) which may itself 
aggravate the metabolic acidosis of renal failure. Diabetic diarrhoea 
(Malins et. al., 1968) and gastroparesis (Campbell et. al., 1977) causing nausea 
and vomiting are sometimes hard to distinguish from the gastro-intestinal 
symptoms of uraemia. Impotence and profuse sweating are also common 
manifestations of autonomic neuropathy in uremic patients (Watkins, 
1973). Neurogenic bladder, arterial disease and medial calcification of 
large arteries are present in almost all diabetic patients with advanced 
renal disease (white et. al., 1971). 
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PATHOGENESIS OF DIABETIC 
GLOMERULOPATHY 
Hemodynamic Considerations 
Renal hemodynamics play a crticial role in the progression of dia-
betic nephropathy and probably contribute to its initiation. In 1952, Fiaschi et. al., 
reported a supeenormal glomerular filtration rate in diabetes under stable 
metabolic control. Other workers have confirmed this finding and have 
extensively investigated the phenomenon (Stalder et. al., 1959, Ditzel 
et al., 1967, Mogensen, 1971). Mogensen described a 40% increment in 
glomerular filtration rate (GFR) in 11 young adult patients with newly 
diagnosed type I diabetes when compared with values in normal subjects 
of similar age (Mogenson et. al., 1971). This marked hyperfiltration is related 
to the patient's metabolic status because the decrease of blood sugar level 
over the course of several days to weeks by standard insulin therapy 
which tends to return GFR to near normal values (Mogensen, 1971). 
However, complete normalization is not rapidly achieved, since even strict 
metabolic control when extended over period as long as I week in young 
diabetics, lowers GFR but fails to normalize it completely (Sandahl-
Christiansen et. al., 1981). 
Elevated blood sugar has been incriminated for glomerular 
hyperfiltration, but the degree of elevation of GFR has been modest with 
increments between 6% and 15% reported after intravenously induced 
hyperglycaemia in normal patients (Sandahl-Christiansen et. al., 1981, 
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Mogensen et. al., 1971; Brochtner-Mortensen, 1973; Mogensen et. al.. 
1981). The means by which hyperglycaemia elevates GFR is uncertain, 
but activation of the tubulo-glomerular feedback and/or provocation 
of vasodilatory prostaglandin release have been proposed (Blantz et. al., 
1982, Woods et. al., 1987, Sene et. al., 1988, Kasiske et. al., 1985). Lack of 
Insulin per se (Sandahal-Christiansen et. al., 1981) can-not account for elevated 
renal plasma flow and filtration rate in insulin-dependent diabetes mellitus. The 
heightened glomerular pressure imply a more subtle renal hemodynamic 
action of insulin independent of its effect on glucose (Scholey et. al., 1989). 
Increased levels of glucagon and growth hormone is capable of 
inducing an increase in GFR in normal subjects when the exogenous 
hormone is administered in doses that lead to levels comparable with those 
found in the hyperglycaemic diabetic patient (Parving et. al.. 1980; Sandahal-
Christiansen et. al., 1981; Lundback, 1976). However increments in GFR 
achieved have been generally substantially less than the usual increments 
observed in the insulin dependent diabetic patients. Furthermore, the 
plasma levels of growth hormone and glucagon do not correlate with 
GFR in diabetics (Wiseman et. al., 1985). Increased dietary protein intake 
elevates GFR and renal plasma flow in normal subjects (Pullman et. al., 1954: 
Hostetter, 1986; Kupin et. al., 1987) and patients with diabetes (Ter Wea 
et. al., 1987; Wiseman et. al., 1987; Wiseman et. a!., 1984). Ketone body 
infusions augment GFR and plasma flow, however, the critical role of 
these substances in producing an increased CJFR is dubious since 
hyperfiltration occur without ketosis (Trevisan et. a!., 1983). Reduci.ons in 
vascular myo-inositol levels, consequent to hyperglycaemia and increased 
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sorbitol production, has been suggested as a factor favoring renal 
vasodilation and as a major pathogenetic mechanism in several diabetic 
complications (Goldfarb et. al., 1986; Greene et. al., 1987). However conflicting 
data also exists as to the role of Sorbitol accumulation in altering renal 
hemodynamics (Greene et. al., 1987). 
The changes in circulating levels and vascular responsiveness to 
several classic vasoactive hormones may be altered in diabetes (Altura et. al., 
1979). Depressed renin levels in animals with early diabetes (Christlieb 
et. al., 1974) as a consequence of the volume expansion, augmented 
systemic pressor response to exogenous angiotensin II on glomeruli 
(Ballermann et. al., 1984) have been recognized in early diabetes. In these 
studies, the number of angiotensin II receptors was diminished in diabetic 
glomeruli, indicating that the typical up-regulation of receptors with 
suppression of renin did not occur in glomeruli (Ballermann et. al., 1984). 
Finally, a recent report describes an augmented renal vasodilation and 
GFR elevation after captopril treatment in diabetics receiving aminoacid 
infusion compared with similarly treated non-diabetic subjects t^Slomowitz 
et. al., 1988). These observations do adumbrate a special dependence of 
the diabetic renal circulation on the renal angiotensin system. 
Disturbances in catecholamine and prostaglandin production 
and/or vasoresponsiveness have also been demonstrated in a variety of 
circumstances in diabetes (Kasiske et. al., 1985; Altura et. al., 1979; Gerrard 
et. al., 1980; Jeremy et. al., 1983). A substantial reduction in renal blood 
flow and filtration rate with indomethacin administration (Koch-Jensen 
et. al., 1986). Increased amounts of vasodilatory prostaglandins isolated 
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from diabetic rats glomeruli (Schambelan et. al., 1983) point to a role for 
altered renal prostaglandin production in hemodynamic changes of early 
diabetes (Kasiske et. al., 1985; Gambradella et. al., 1988). 
Add'.tional vasoactive substances like hepatic production of 
glomerulopressin (del Castillo et. al., 1977), hepatic substance as serotonin 
(Alvestrand et. al., 1989), elevated atrial natriuretic peptide (Ortola et. al., 1987) 
and elevated Kinin production (Harvey et. al., 1987) have been proposed as 
contributors to the altered renal hemodynamics of diabetes. At present time, 
the neuro hormonal stimulus for increased filtration rate in early diabetes 
remains unknown. 
The intrarenal hemodynamic basis for the elevated filtration 
rate has been more firmly established, even within the constraints of human 
studies. Glomerular filtration is governed by four factors: First, glomerular 
plasma flow influences the mean ultrafiltration pressure and is thereby 
directly related to GFR (Brenner et. al., 1977). Elevated plasma flows have 
been reported in diabetics with increased GFR (Mogensen, 1973, 
Vazquez et. al., 1981, Sandahl-Christiansen et. al., 1981). The second 
determinant of GFR is systemic oncotic pressure which is reportedly 
normal as estimated from plasma protein concentrations (Mogensen, 
1971). The third determinant of GFR is glomerular t ranscapi l lary 
hydraulic pressure difference which cannot be measured in humans. The 
last determinant is the glomerular ultrafiltration coefficient which is 
viewed as the product of the capillary hydraulic conductivity and the 
surface area of the capillary available for filtration. It has been suggested 
that hyperfiltration results atleast in part from the increased glomerular 
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surface area (Kroustrip et. al., 1977; 0sterby et. al., 1980). Correlation have 
been developed between morphometrically measured glomerular surface 
area from human renal biopsies and glomerular filtration rate (Hostetter 
et. al., 1981, Hirose et. al., 1980). 
Hyperfiltration observed in early human diabetics was also 
reproduced in adult Munich-wister rats (Hostetter et. al., 1981). In addition 
to s treptozotocin-induced diabetes, alloxan induced diabetic rats, 
pancreatectomized dogs and rats, and two strains of spontaneously diabetic 
mice all demonstrate increased glomerular filtration rates (Del Castillo 
et. al., 1977; Hostetteret. al., 1981). Studies of Hostetter et. al., 1981, of 
streptozotocin induced diabetes in the rat have demonstrated that increments 
in GFR were due to changes in two of the hemodynamic factors governing 
filtration rate. First, increase in single nephron plasma flow was the result 
of reductions in both afferent and efferent arterial resistances. Second 
increments in the glomerular transcapillary hydraulic pressure difference 
contributed to the increase in GFR as well. The calculated glomerular 
ultrafiltration coefficient did not account for the increased filtration rate. 
Michaels et. al., 1981 demonstrated hyper-filtration in early alloxan-induced 
diabetes a change which in their studies was attributable entirely to the 
increase in single nephron plasma flow. Finally Koch-Jensen et. al., 1981 
studying streptozotocin induced diabetes found an increased single nephron 
GFR (SNGFR) together with an increased single nephron plasma flow and a 
heightened transcapillary hydraulic pressure gradient. The early alterations in 
glomerular hemodynamics in IDDM may themselves potentiate or even 
directly cause end-stage diabetic glomerulopathy and its at tendant 
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proteinuria, structural lesions and progressive decline in GFR. This 
hypothesis derived initially from studies of animals with single nephron 
hyperfiltration induced by reduction in renal mass (Hostetter et. al., 1982, 
Zatz et al., 1986). These studies have clearly demonstrated that with 
these extreme increases in SNGFR there is clear evidence of glomerular 
structural damage, including areas of detachment of glomerular epithelial 
cells from underlying glomerular basement membrane (GBM), expansion of 
mesangial areas,fusion of epithelial cell foot processes, and the presenc of 
dense droplets representing endocytosis of plasma protein in glomerular 
and proximal tubule cells (Hostetter et. al., 1981, Steffes et. al., 1978). 
Furthermore, when the increments in SNGFR, glomerular plasma flow, 
and transcapillary hydraulic pressure seen in remnant were blunted by 
dietary protein restriction there was an accompanying reduction in glomerular 
structural lesions and proteinuria. The early hyperfiltration and hyperper-
fusion of the diabetic glomeruli may lead to their ultimate destruction 
(Hostetter et. al., 1982, Zatz et, al., 1986). 
Several possibilities have been suggested for increases in 
glomerular perfusion that might lead to GBM thickening. First an increase 
in transcapillary hydraulic pressure might lead to increases in mesangial 
matrix production. Since the mesangial cells have several features in 
common with smooth muscle cells of large vessels, including contractile 
capability (and the pres^:nce)of ^-ctomyDsin, an increase in their number 
or size might occur with increased wall tension, as occurs in the smooth 
muscle cells of large arteries exposed to increased pressure (Ausillo et. al., 
1980, Webb et. al., 1981). An increase in basement membrane production 
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might also occur in response to the physical stress of increased capillary 
pressure, since the production of collagen in other vascular sites can 
respond to stretch and tension (Leung et. al., 1976). Secondly, the increased 
transglomerular movement of plasma proteins might be associated not 
only with their movement into the urinary space and ultimate proteinuria, 
but also with deposition in the mesangial region and GBM. In addition to 
the compositional changes, such as glycosylation that could enhance 
trapping of such macromolecules, their increased flux into these regions 
might be accentuated by underlying hemodynamic alterations of early 
diabetes (Raij et. al., 1979). Mauer et. al., 1979 have described defects in the 
mesangial clearance of large particles in diabetes. Besides excessive 
mesangial deposition of circulating macromolecules might serve to increase 
mesangial cells and to promote mesangial matrix production a component 
of the ultimate diffuse and nodular expansion of the mesangium seen in late 
diabetes (Mauer et.al., 1979; Velosaet.al., 1977;Grondet. al., 1982). Moreover. 
simple physiological disruption of normal barriers including the endothelial 
and epithelial surfaces because of heightened intracapillary pressures 
(Olson et. al., 1982; Ross et. al., 1976) might occur besides glomerular 
enlargement may promote pathological progression. 
Studies of arterial hypertension and its treatment in clinical 
diabetes offer compelling evidence for hemodynamics in the disease process. 
Arterial hypertension accompanies diabetic renal disease, exacerbates i t s progres-
sion and may determine its occurrence (Krolewski et. al., 1988; Mangili et. al., 
1988; Hasslacher et. al., 1985; Jarret et. al., 1982; Drury, 1983; Parving et. al., 
43 
1981; Watkins et. al., 1972 and Parving et. al., 1987). Parving et. al., 1981 
compared 60 Type I diabetics, who had developed clinical proteinuria but 
who nevertheless had normal serum creatinine with 20 Type I diabetic 
patients without persistent proteinuria, who were matched for sex, age, 
body weight and duration of diabetes. They have also included a comparison 
with 30 non-diabetic subjects, matched for age, sex and body weight. The diabetic 
pat ients with clinical proteinuria had mildly but s ignif icantly 
elevated blood pressures compared with both diabetic and normal controls. 
Hasslacher et. al., 1985, have reported that 44% of diabetics who developed 
persistent proteinuria were previously hypertensive as compared with 
7% prevalence in those who do not. The prevalence increased to over 90% 
when serum creatinine began to rise. Finally, a family history of essential hyper-
tension appears to increase the risk at a diabetic developing renal 
disease. Krolewski et. al., 1988, found a more than threefold increase in 
the risk of nephropathy in diabetics who had a parent with hypertension. 
No differences between non-proteinuric diabetics and normai subjects were 
found. It has been suggested that type I diabetic patients with diabetic 
nephropathy and even normal serum creatinine, have an increased prevalence 
of hypertension, and that rising arterial pressure may appear before major 
depression of filtration rate. 
The mechanisms giving rise to hypertension could be the develop-
ment of essential hypertension, increased activity of the erythrocyte sodium-
lithium antiporter (Krolewski et. al., 1988; Mangili et. al., 1988) which could 
be a marker for risk of nephropathy in diabetics (Krolewski et. al., 1988; 
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Mangili et. al., 1988; Weder 1986), sodium retention (O'Hare et. al., 1986 & 
Brochner-Mortensen 1973). The extracellular and plasma volume expansion is 
viewed as the product of either or both of two factors. First, the elevation 
of extracellular glucose in the diabetic serves as an osmotic force to 
redistribute fluid from the intracellular to the extracellular space, thereby 
increasing extracellular space and fluid plasma volume. The increase in 
plasma volume might be an early stimulus to increased cardiac output that 
would translate to sustained hypertension (Axelrcjd, 1975). Second, 
extracellular fluid volume may be enhanced in the diabetic by a tendency to 
increased sodium reabsorption by the kidney. The exogenous pulses of insulin in 
Type I diabetic and perhaps more likely the heightened levels of 
endogenous insulin in type II diabetics, could increase sodium reabsorption, 
further expanding volume and ultimately yielding systemic hypertension. 
Recent attention has focused on the hypertensive effects of heightened 
insulin levels in insulin resistant states (Ferranini et. al., 1987). 
METABOLIC PATH 
Hyperglycaemia 
There is no doubt about the relationship between abnormal glycemic 
milieu and microvascular complications. (Williamson et. a!., 1977, Steffes 
et. al., 1985). This is further supported by other studies (Becker et. al., 1960; 
Ireland et. al., 1967; Brown et. al., 1982; Lee et. al., 1974; Mauer et. a!., 1975; 
Steffes et. al., 1980; Rasch 1979, 1980). Indeed in humans, the evidence of 
a straightforward causal relationship between hyperglycaemia and renal 
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disease is less compelling than it is in the animal model. The development 
of clinically overt renal disease is not linearly related to the duration of 
diabetes and affects only 35 to 50% of patients. The majority of the 
patients with diabetes escape renal failure and although some histologic 
damage occurs in their kidneys, their renal function remains essentially 
normal until death. Kidneys from non-diabetic human donors develop 
typical lesions of diabetic glomerulopathy when transplanted into a diabetic 
recipient (Mauer et al., 1983) but the rate of development of the lesions 
varies greatly in a manner independent of the blood glucose control over 
the years (Mauer et. al., 1989) and thereforeiit appears that in humans 
hyperglycaemia is necessary but not sufficient and other possibly 
non-environmental factors are needed for the manifestation of the clinical 
syndrome. 
Non-enzymatic giycosylation 
Excess glomerular basement membrane giycosylation, as seen in 
diabetes, may lead to an increase in the degree of cross-linking of disulfide 
bridges between collagen components via increased oxidation of sulfhydryl 
groups. Rotatory shadowing electron microscopy of glycosylated basement 
membrane components has revealed increased collagen IV cross-linking and 
altered molecular morphology (Brownlee et. al., 1988). 
However, the pathogenic consequences of enhanced cross-linking in 
the kidney remain obscure. It has been suggested that increased binding 
of circulating plasma proteins to structural components in the glomerular 
basement membrane and mesangial matrix by the presence of the reactive 
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carbonyl group on the glucose, may account for the linear deposition of 
albumin and Ig G observed along glomerular and tubular basement 
membranes in diabetes (Brownlee et. al., 1983). Reduced degradation of 
fibrin by plasmin (Brownlee et;«l/1983),non-enzymatic glycosylation of 
fibronectin inhibiting its adhesion to matrix components (Cohen et. al., 1984) 
and enhancing its binding to glomerular basement membrane (Cohen et. al., 
1987) may result in alterations in the integrity and adhesive properties 
of the matrix and promote the development of defects in the selective 
properties of the capillary barrier.Alteration of the charge distribution of 
glycosylated albumin could provide a mechanism for the abnormal flux 
of modified albumin across the glomerular membrane (Cohen et. al., 1981) 
however these results have not been confirmed by Nakamura and Myers 
et. al., 1988). Recently a membrane-associated macrophage receptor that 
specifically recognizes advanced glycosylation end-products in proteins has been 
identified (Vlassara et. al., 1986). The binding of this receptor to protein 
with advanced glycosylation end-products induces synthesis by macrophages 
of monokines (interleukin-1 and Tumor necrosis factor). In conclusion, 
excessive formation of glycosylation products in the glomerulus may lead 
to enhancement in deposition of basement-membrane like material and 
circulating proteins in the mesangium, interfere with mesangial clearance 
mechanisms and alterations in the macrophage removal system and so 
contribute to mesangial expansion and glomerular occlusion. 
The Polyol Pathway 
In the normal kidney, aldol reductase is present in the papilla, 
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glomerular epithelial cells, distal tubular cells and probably mesangial cells 
(Ludwigsonet. al., 1980;Kikkawaet.al., 1987). In many tissues, the physiologic 
significance of aidol reductase is difficult to define, but in the renal 
medullary cells of the kidney, its primary role seems to be in the generation 
of sorbitol, an organic osmolyte in response to the high salinity in the 
medullary interstitium. 
Sorbitol would aid in preventing osmotic stress (Burg 1988). In-
creased concentration of sorbitol and/or a reduced intracellular concentration of 
myoinositol might contribute to diabetic complications via an upset of 
cellular osmoregulation (Cogan, 1984; Kador et. al., 1985). Depletion of 
tissue myoinositol has been observed in association with enhanced activity 
of polyol pathway in sciatic nerve, lens, retina and glomeruli of humans 
and animals (Pugliese et. al., 1990). 
In glomeruli obtained from diabetic rats, the increased flux through 
the polyol pathway, with accumulation of sorbiol, depletion of myoinositol 
and reduced Na+/K+- ATPase activity has been shown to be preventable 
by the administration of the aldose reductase inhibitor sorbinil. The increased 
GFR and proteinuria in rats with streptozotocin-induced diabetes have also 
been reported to be reduced by inhibi tors of aldol reductase or 
by supplementation of myoinositol (Goldfarb et. al., 1986; Beyer-Mears 
et. al., 1986), however, were not confirmed by other workers (Daniels et. al., 
1989). There is some evidence that renal clearance of low-molecular 
weight proteins may be affected to a greater degree by sorbinil than is the clearance 
of proteins the size of albumin or larger, which more directly 
48 
reflect the glomerular barrier permeability function (Beyer-Mears et. al., 
1986). The sorbinil may act as a vasoconstrictor (Coco et. al., 1988; Mower 
et. al., 1989) and lower renal prostaglandin synthesis (Frey et. al., 1989), 
thereby modifying renal haemodynamics independently of the aldose 
reductase pathway. The sulindac, a potent inhibitor of prostaglandin synthesis, 
also blocks aldose reductase, suggesting that the action of certain aldose-
reductase inhibitors may be similar to that of nonsteroidal antiinflammatory 
drugs (Jacobson et. al., 1983). Although sorbinil has been shown to prevent 
renal hypertrophy in galactose-fed rats (Beyer-Mears et. al., 1983), all 
authors concur that aldose reductase inhibitors have no effect on the 
increased kidney weight in animals with streptozotocin- induced diabetes. 
Moreover, in the rat, the histologic lesions of the glomerular disease after 
6 months of diabetes were unaffected by administration of statil, another 
aldose-reductase inhibitor (Rasch et. al., 1990). In contrast Tilton et. al., 1989 
found, using three different aldose- reductase inhibitors, a reduction in the 
clearance of 51 Cr-ethylenediamine tetracetic acid (EDTA), in albuminuria 
and in the permeation of 125 I-bovine serum albumin into the vascular wall 
in the streptozotocin diabetic sprague- Dawley rat, and concluded that 
"Virtually all of the early functional and structural renal and vascular changes 
associated with diabetes in animals are aldose reductase-linked phenomenon". 
They have further shown that myoinositol-supplementation reduce or 
normalize GFR, renal blood flow, urinary protein excretion and serum 
albumin permeation of blood vessels (Pugliese et. al., 1990). 
The diversity of effects of aldose-reductase inhibitors persists in 
the few studies carried out in humans. Reductions of GFR (Pederson et. al., 
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1991) and AER (Blohme et. al., 1989) in patients with IDDM have been 
claimed, but no effects have been reported in a controlled study of 
microalbuminuric patients with NIDDM (Cohen et. al., 1989). 
Biochemical abnormalities of Extracellular Matrix 
Studies in diabetic animals suggest that the rates of synthesis of 
matrix and glomerular basement membrane are significantly accelerated. The 
activity of lysyl-hydroxylase, an enzyme involved in the hydroxylation of peptide-
bound lysine during collagen biosynthesis (Khalifa et. al., 1975) and collagen 
(Brownlee et. al., 1979) has been shown to be increased in the glomeruli of 
diabetic rats. 
Glycosaminoglycan (GAG) polysaccharides account for 90% of the 
total carbohydrate component of the glomerular basement mebrane, with 
sialoproteins constituting the remainder. The principal GAG in the 
glomerular basement membrane is heparan sulfate, which together 
with sialic acid, contributes to the negative charge of the glomerular 
capillary wall and thereby to the charge selectivity properties of the filtration 
barrier (Brenner et. al., 1978; Farquhar 1981). In diabetes, there is reduced 
de novo synthesis of glomerular heparan sulfate, and the total GAG content 
in the glomerulus and glomerular basement membrane is reduced 
(Parthasarathy et. al., 1982; Kanwar et. al., 1983; Rohrbach et al., 1983; Cohen 
et. al., 1984; Wu Y-Y et. al., 1987). The heparan sulfate content of the 
glomerular bas<>ment membrane has been found to be decreased in patients 
with IDDM with nephropathy (Shimomura et. al., 1987). Other have reported 
a reduction in sialic acid components (Westberg et. a!., 1973; Kefalides et. al.. 
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1974; Wahl et. al., 1982). A loss of negative charge of the glomerular 
membrane may be responsible for foot process fusion, with consequent 
obliteration of the slit diaphragm and could partly explain the albuminuria 
of diabet ic nephropathy. Besides elevated activity of the enzyme 
glycosyltransferase, responsible for the attachment of glucose to the 
glycoprotein has also been reported but others have failed to confirm 
these findings (Westberget. al., 1973; Kafalides 1974; Wahl et. al., 1982; Spiro 
et. al., 1971; Beisswenger et. al., 1972; Beiss wenger et. al., 1976). 
Glucotoxicity 
The cultured human endothelial cells, after prolonged, although 
not acute, exposure to high ambient glucose concentrations, display 
consistent alterations in cell replication and maturation which can not 
be ascribed to abnormalities of the polyol pathway (Lorenzi et. al., 1987, 
Lorenzi et. al.,, 1985,Lorenzi et. al., 1987). These abnormalities are associated 
with evidence of damage to DNA (Lorenzi et. al., 1986) which has also been 
demonstrated in peripheral blood lymphocytes from patients with poorly 
controlled diabetes but not from those with better control (Lorenzi et. al., 
1987). Cultured endothelial cells are increased in diabetic basanent manbrane 
(Cagliero et. al., 1988) and also show abnormal expression of tissue factor 
in RNA in response to thrombin and interleukin-1 after prolonged exposure 
to high glucose concentrations (Boeri et. al., 1989). 
Whether glucose exerts a direct toxic effect on human endothelial 
cells in vivo is currently unknown, but it is of interest that abnormalities 
of endothelial cell function have been implicated in the increased frequency 
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of cardiovascular disease that is a feature of diabetic nephropathy. Such 
abnormalities evidenced by raised plasma levels of Von-Willebrand factor 
(Jensen et. al., 1989) by a decreased release of some plasminogen activator 
in response to exercise (Jensen et. al., 1989) are present even before overt 
nephropathy develops. 
Familial/Genetic Pathways 
Familial clustering of diabetic kidney disease has been reported. In 
IDDM, 83% of diabetic siblings of probands vwth diabetic nephropathy have 
evidence of nephropathy, compared wath only 17% of diabetic siblings of 
probands without nephropathy, a significant five-fold difference (Table III). 
Table-Ill. Prevalence of Diabetic kidney disease (End-stage Renal Failure 
and elevated Albumin Excretion rate) in diabetic siblings of 
patients with insulin-dependent diabetes withor without 
nephropathy. 
(% of siblings) 
Kidney Function Patients with Nephropathy Patients wihtout 
Nephropathy 
End-stage renal failure 12(41.4%) 0(0)* 
Raised albumin 12(41.4%) 2(17)* 
excretion rate(>45 mg/24 h) 
Normal albumin 5(17.2%) 10(83)* 
Table is adopted from Seaquist et. al., 1989* P<01. 
A familial incidence on development of nephropathy has also been 
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described in Pima Indians with NIDDM (Pettitt et. al., 1990). A familial 
predisposition to raised blood pressure has been suggested by some- though 
not all-reports, as a possible contributing factor to the susceptibility to 
nephropathy in diabetes (Viberti et. al., 1987), Krolewski et. al., 1988, Jensen 
et. al., 1990).Parents of patients with IDDM who have proteinuria were 
found to have significantly higher arterial pressure or a higher prevalence of 
hypertension than matched parents of non-proteinuric patients with IDDM 
(Table IV). 
Table-IV. Blood pressure (BP) and frequency of Hypertension in parents 
of patients with Insulin-dependent diabetes with and without 
Nephropathy (DN). 
Parents of patients Parents of patients 
withDN without DN 
Systolic BP(mm Hg) 161 ±27 146 ±21* 
mean ± SD 
Diastolic BP(mm Hg/ 94 ± 14 86 ± 11 * * 
mean ± SD 
Frequency of hypertension(%) 77 45 * * 
* P<.02 Adapted from Viberti et. al., 1987 and Krolewski et. al., 1988. 
** P<.05. 
More recently, familial clustering of cardiovascular disease has been 
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found in patients with IDDM and nephropathy and a parental history of cardiovas-
cular disease has been shown to increase the risk of kidney disease in the diabetic 
offspring (Earle et. al., 1992). The rates of sodium-lithium counter- transport have 
been found to be higher in proteinuric pat ients with diabetes 
and their parents than in matched long-term normoalbuminuric controls 
(Krolewski et. al., 1988, Jensen et. al., 1990, Mangili et. al., 1988, Walker et. al., 
1989). Microalbuminuric diabetic patients, a group at increased risk of 
overt nephropathy have also been found to have higher rates of sodium lithium 
countertransport (Jones et. al., 1990). The association between sodium-
Lithium countertransport activity, hypertension and lipid abnormalities in 
the context of susceptibility of diabetic renal and vascular disease are 
unclear but they could be related to factors involved in the control of 
insulin sensitivity (Lopes de Faria et. al., 1992). In a study of short-term, 
non-clinically proteinuric diabetic patients with arterial hypertension (Blood 
pressure > 140/90 mm Hg), the hypertensive patients with higher rates of 
sodium lithium counter transport were more insulin-resistant and in addition 
had higher rates of albumin excretion, increased total body exchangeable 
sodium, enlarged kidneys, and left ventricular hypertrophy (Trevison et. al., 
1992). 
These fmdings suggest that it is the diabetic hypertensive subjects 
with high sodium-Lithium counter transport who displays those features 
i.e. albuminuria, left ventricular and renal hypertrophy and insulin 
resistance that have been related to renal and vascular injury (Chavers et. al., 
1989, Foster DW 1989, Silberberg et. al., 1989, Sampson et. al., 1990). Recently, 
leuocytes and cultured skin fibroblasts from IDDM pat ients with 
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albuminuria have been reported to have elevated sodium-hydrogen antiport 
activity (Trevisan et. al., 1990, Ng et. al., 1990). Moreover, an increased 
(3H) thymidine incorporation into DNA of skin fibroblasts of diabetic 
patients with nephropathy has been documented (Trevisan et. al., 1990). 
These findings are consistent with the view that the cells of diabetic patients 
who develop nephropathy have an intrinsic enhanced capacity to proliferate 
and that this phenomenon is associated with high rates of sodium-
hydrogen exchanger activity. The activity of sodium-hydrogen antiport 
possibly genetically determined, controls cell growth and hypertrophy on one 
hand and intracellular sodium homeostasis on the other. The environmental 
changes brought by diabetes could lead to dysregulation of these mechanisms 
in susceptible individuals and induce cell hypertrophy and hyperplasia 
contributing to glomerular hypertrophy and mesangial expansion in the kidney, 
as well as tubular hypertrophy and hyperplasia. Increased renal sodium reabsorption 
increasing perfusion pressure, would lead to increased 
intraglomerular pressure, which determines at least in part, the increase in 
GFR and maybe responsible for the disruption of glomerular membrane 
permeability properties generating proteinuria. Further, progressive 
mesangial expansion would lead to glomerulosclerosis and further disruption 
of glomerular basement membrane permeability selective properties. The 
insulin resistance associated with excessive growth and the consequent 
hyperinsulinemia may cause lipid abnormalities that in setting of vascular 
hyperpermeability characteristic of diabetic microvascular disease (Feldt-
Rasmussen 1986), would further aggravate the renal histologic damage 
(Moorhead et. al., 1982), and contribute, in combination with hypertension, 
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to the accelerated atherosclerosis of diabetic renal failure. 
PATHOLOGYOF DIABETIC NEPHROPATHY 
The renal morphologic changes associated with diabetes melUtus 
were first described by Kimmelstiel and Wilson in 1936 and confirmed and 
extended by other workers (Fahr 1942; Spiihler et. al., 1943). Both the early 
autopy and biopsy series and later studies (Taft et. al., 1990; Kamenetzy et. al., 
1974) have shown that the histologic findings in kidneys of patients with IDDM and 
NIDDM are similar. 
Light Microscopy 
The nodular lesion described by Kimmelstiel and Wilson in 1936 
has for a long time been considered virtually specific for diabetes (Bell 
1953, Gellman et. al., 1959). Reports that it could be found in the absence of 
diabetes have not withstood critical review (Tchobroutsky, 1979). The 
nodules are well-demarcated hard masses., eosinophilic and periodic acid-
Schiff (PAS)-positive, located in the central regions of peripheral-glomerular 
lobules, usually contain pyknotic nuclei and not infrequently foam cells. The 
location and morphogenesis of the nodules have been the subject of long 
dispute, as reflected by the use of both terms "intracapillary" and "inter-
capillary" to describe them.. Recently evidence (Saito et. al., 1988) seems to 
establish the mesangium as their site of origin and extends the original 
suggestion that mesangial disruption and lysis of the lobule center was related 
to prior microaneurysmal dilatation of the associated capillary, followed by 
a laminar reorganisation of the mesangial debris (Blood worth, 1978). 
The lesion, when present is pathognomic for diabetes and its inci-
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dence varies considerably from 12 to 46% in different series, which included 
both IDDM and NIDDM cases, probably because of differences in location 
(Heptinstall, 1983). Nodules have been found in 55% of an autopsy series 
of Pima Indian patients with NIDDM (Kamenetzy et. al., 1974). Nodules 
are not seen in the absence of the diffuse lesion, and this reflects their 
appearance only after a long-period of disease (14 years in the series of 
Gellmenet. al., 1959). 
The diffuse glomerular lesion comprises an increase of the 
mesangial area of capillary wall thickening, with the mesangial matrix 
extending to involve the capillary loops. In its early stages, it may be difficult to 
distinguish the minor mesangial expansion from changes present with aging or 
from other glomerular pathology (Watkins et. al.„ 1972). In more severe cases, 
the capillary wall thickening and the mesangial expansion lead to capillary 
narrowing and eventually to complete hyalinisation. In this state, 
periglomerular fibrosis is often present. The distribution of the diffuse 
lesion is non-uniform, both among lobules of the same glomerulus and 
between different glomeruli leading to appearances suggestive of transition to 
nodule formation. The thickening of the capillary walls tends also to be 
non-uniform, and this is particularly evident when histologic changes are not 
very severe. This lesion is more frequent than the nodular one, but again its 
incidence varies in different series (Heptinstall 1983). In a large autopsy 
study, however, changes compatible with diabetic glomerul osclerosis were found 
in as many as 90% of IDDM patients with disease duration of more 
than 10 years (Thomsen,1965). In patients with NIDDM, the reported 
prevalences of these changes ranges between 25 and 51% (Dumler, et. al.. 
57 
prevalences of these changes ranges between 25 and 51% (Dumler, et. a!., 
1987; Bell,1953; Heptinstall, 1983). 
The exudative lesions are highly eosinophilic, rounded homogenous 
sturctures seen in the capsular spaces, overlying a capillary loop (Fibrin Cap) 
or lying on the inside of Bowman's capsule (capsular drop). They are 
non-specific, containing various proteins and sometimes lipid material, and 
similar lesions are seen in a variety of other renal conditions. 
In IDDM patients, an increase in glomerular volume and in luminal 
volume are noted in 1 to 6 years often diagnosis (Osterby et. al., 1977). The 
late hypertrophy in which the number of nuclei is increased in patients with 
16 or more years of disease is increased and the glomerular volume becomes 
even larger. This late hypertrophy may be an expression of compensatory 
growth in the face of progressive glomerular loss (Gundersen et. al., 1977; 
Osterby et. al., 1983). This hypertrophy has not been found in NIDDM 
(Schmitz et. al., 1988). Bell 1953, reported that both afferent and efferent 
arterioles could be affected in diabetes and showed that hyaline material 
progressively replace the entire wall structure. These lesions are often present 
in the absence of hypertension and the involvement of efferent vessel is 
highly specific for diabetes. This arteriolar change may be the first change 
detectable by light microscopy at 2 years in non-diabetic kidneys transplanted 
into diabetic patients (Mauer et. al., 1976). 
A variety of non-specific changes are seen in the tubules and 
interstitium similar to those seen in other forms of progressive renal disease. 
The Armanni-Ebstein lesion is the result of accumulation of glycogen in 
tubular cells of cortico-medullary region in patients with profound 
58 
insulin. More subtle tubular changes, consisting of vacuolization, a decrease 
in the intercellular spaces normally present between the macula densa cells. 
and a significant increase in the contact area between them and the 
extragiomerular mesangial cells of Goormatigh, have been described at the 
u l t r a structural level in the streptozotocin-diabetic rat. It was suggested that 
these changes may represent a morphologic counterpart to disturbed 
tubuloglomerular feedback which might contribute to hyperfiltration in 
diabetes (Rasch et. al., 1988). 
Immunopathology 
Westberg and Michal 1972, confirmed the observations of thin 
linear staining of the glomerular basement membrane for IgG, IgM, albumin and 
fibrinogen in kidneys of patients with IDDM and concluded that it represented 
a non-specific consequence of increased permeability rather than an 
expression of immunologic binding. The presence of these linear positivit\ 
for IgG and albumin extended along not only the glomerular basement 
membrane but also the Bowman's capsule and especially the outer aspect of 
the tubular basement membrane, which was considered specific for diabetes 
(Miller et. al., 1976). These findings were supported by demonstration of similar 
staining in kidneys from non-diabetic donors transplanted into IDDM patients 
(Mauer et. al., 1976). 
Increased mesangial amounts of type IV and V collagen laminin, 
and fibronectin and the presence of antigens normally expressed in fetal 
g lomeru l i only have been shown by immunofluorescence techniques 
(Falk et. al., 1983). Collagens of type I (Glick et. al.. 1990) and type VI but 
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not of type III (Ikeda et. al., 1990) have also been described in diabetic 
mesangium. Type VI collagen which is probably synthesized only by 
mesangial cells and therefore absent from the basement membrane has 
been found to be increased about three fold in the kidneys of those 
with long-standing diabetes as compared with kidneys of non-diabetic controls 
(Mohan et. al., 1990). The possibility of anomalies in the contractile 
properties of the mesangium has been considered following the 
demonstration of increased amounts of actomyosin (Scheinman et. al., 
1974). Fibrin products as well as IgG and complement component have been 
found in the exudative lesions of the glomerulus and of the arterioles 
(Heptinstall 1983), suggesting a role for coagulation process in the genesis 
of glomerulosclerosis (Westberg et. al., 1972, Far^uhar et. al., 1972). 
Electron Microscopy 
Glomerular basement membrane thickening is a prominent finding 
in the kidneys of diabetic patients, particularly in IDDM subjects in whom 
it is absent at diagnosis (0sterby-Hansen 1965) becoming detectable after 
2 to 5 years of disease (0sterby 1975). The increased synthesis taking place 
during this period is reflected, in the 80% increase in the area of the 
peripheral capillary wall found in young subjects with IDDM within months 
of diagnosis (Kroustrup et. al., 1977). In advanced stages, the basement 
membrane can become very thick, and particularly so in association with 
nodular lesions (Kimmelstiel et. al., 1966), whereas in early disease, the 
increase in thickness is even, a marked irregularity in its width appears 
later (0sterby et. al., 1983). Localized areas of electron-lucent material 
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can make up to 10% of toal volume of the basement membrane and 
between 1 and 6% of the capillary length is lined by abnormally thin 
membrane (0sterby et. al., 1987). Throughout all the stages upto sclerosis, 
features suggestive of immune deposits are absent, althought subendothelial 
fibrillar electron-dense material interpreted as fibrin-fibrinogen products 
has been described (Farquhar et. al., 1972). 
Soon after the persistent proteinuria, the epithelial cells foot 
processes remain discrete (Ireland et. al., 1967), however, with further 
progression of disease, the foot processes appear wider in cross section 
and length of the filtration slits tends to decrease (Ellis et. al., 1987), 
eventually, podocyte effacement and fusion are noted (Kimmelstiel et al., 
1966). An increase of the fractional volume of the mesangium,initially 
involving an expansion of the matrix component, follows the thickening of 
the glomerular basement membrane (0sterby 1973). Its delicate strands 
anastomose and widen, and collagen fibrils become detectable with 
progression of the disease. The case of the typical nodules seems to 
correspond to local accumulation of these compounds (Kimmelstiel et. al., 
1962; Dach's et. al., 1964) while their laminated periphery may derive 
from expanded and folded basement membrane (Ikeda et. al., 1990). In 
more advance stages, the fractional volume of the mesangium become more 
than double the value found in normal controls (Mauer et. al., 1984). 
The exudative lesions appearing as finely granular electron-dense 
material in the arteriole spreads from an initial subintimal location towards 
the media, sometimes to its near replacement. The "capsular drop" corresponds to 
accumulation of this material between the epithelial cells and Bowman's 
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capsule basement membrane, whereas the "fibrin cap" represents its presence 
along the endothelial side of the glomerular basment membrane (Heptinstall 
et, al., 1983). Endothelial cell changes are not prominent in diabetes. 
Structure-Function Relationship 
Increased glomerular volume is a salient feature in the kidneys 
of patients with IDDM and is part of a generalized hypertrophic process 
that also involves the tubules and results in increased kidney volume. 
Large glomeruli are probably a necessary condition for the early hyper-
filtration of IDDM. In diabetes mellitus also, relatively large kidneys persist 
with advancing renal failure. More than 30 years ago, Gellman et. al., 1959 
were the first to show that the nodular lesions are of little functional 
significance and that it is the degree of diffuse glomerulosclerosis, 
encompassing changes in the glomerular capillary and the mesangial region 
that correlates with the clinical manifestations of worsening renal function. 
In the early phases of IDDM, the increase in luminal volume and filtering 
surface area shown by light and electron microscopic studies offers a 
structural counterpart to the higher GFR (Kroustrep et. al., 1977). With 
advancing renal disease, no correlation is seen between the width of the 
thickened glomerular basement membrane but a close association has 
been reported between these changes in function and mesangial expansion 
(Osterby et. al., 1990). A fractional mesangial volume in excess of 37% has 
been claimed to characterize patients with clinical proteinuria (Mauer et. al., 
1984). Mesangial expansion also correlates inversely with the capillary 
filtering area, a variable closely associated with GFR, from levels of 
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hyperfiltration of markedly reduced renal function (Ellis et. al.. 1986, 
Thomsen et. al., 1984). It has therefore been suggested that it is the 
expansion of the mesangium, with the attendant reduction in glomerular 
filtration surface area, that is responsible for the progressive loss of renal 
function in IDDM. However, it should be remembered that there is overlap 
between the fractional mesangial volume of patients with and those without 
proteinuria (Thomsen et. al., 1984, Steffes et. al., 1989) making the 
prognostic significance of this variable open to question. Morphometric 
parameters do not correlate in IDDM patients with albumin excretion rate 
up to 40 mg/day (~ 30 ng/min). With higher albumin excretion rates, 
fractional volume of mesangium was significantly increased and a minor 
reduction in creatinine clearance and an elevation in blood pressure 
were observed (Chavers et. al., 1989). Similar findings in NIDDM patients 
have been reported (Inomata et. al., 1989). The data confirm the reliability 
of persistent microalbuminuria and attendant blood pressure elevation as 
clinical markers of significant renal damage (Wiseman et. al., 1984). 
PREVENTION OF DIABETIC RENAL DISEASE WITH SPECIAL REFER-
ENCE TO MICROALBUMINURIA 
Six sets of recommendations on the prevention of diabetic 
nephropathy, with special reference to microalbuminuria, have been 
published (Viberti et. al., 1994, Anon, 1994, Jerums et. al.,, 1994, Consensus 
development conference 1994, Bennett et. al., 1995, Striker, 1995). The back-
ground to this activity was the large and increasing number of diabetic 
patients in whom end-stage renal failure (ECRF) develops and who 
therefore require dialysis or renal transplantation. Throughout the world 
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about a half million patients are registered as being on renal replacement 
therapy, and diabetic nephropathy is the cause in nearly one-fifth of them 
(Mogensen, 1994). These data are extrapolated from countries which have 
registries but in many areas, especially in the densely populated countries 
of the Far East, accurate information on number of patients with ESRD is 
not yet available. Moreover, the half-million figure probably underestimates 
the number of diabetic patients with ESRD because selection criteria for 
renal replacement therapies varies from country to country. Both IDDM and 
NIDDM diabetic patients contribute to the increase in ESRD. Prevention 
of diabetic renal disease, or atleast the postponement or slowing down of 
the disease process, has emerged as a key issue. Our strategy is to develop 
programmes for all patients with diabetes, focused on early detection of renal 
disease followed by intervention. 
Increased urinary albumin excretion also predicts early mortality 
in NIDDM (Jarret et. al., 1984, Mogensen 1984) and the same relation is 
observed in the general population too (Yudkin et. al., 1988, Damsgaard et. al.. 
1990, Mogensen 1994, Feldt-Ras-mussen et. al., 1994). The association with 
vascular disease is important (Yudkin et. al., 1988, Mogensen 1994, Feldt-
Rasmussen et. al., 1994). Microalbuminuria is common in poorly treated 
individuals with essential hypertension (Parving et. al., 1974). It is not yet 
known if screening for microalbuminuria and subsequent treatment will 
improve outcome in hypertensive non-diabetic patients or in the general 
population. In diabetes, however, the evidence is strong. 
Mogensen et. al., 1995 aimed at a consensus on the detection 
prevention, and treatment of diabetic nephropathy. 
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Screening : Several procedures for urine sampling have been proposed 
24 hour urine collection, overnight collection, short term collection in 
the clinic, and urine albumin-creatinine ratios in random or early morning 
(first voided) urine. The screening and confirmatory procedures for 
microalbuminuria are summarised in Table V. 
There are no formal studies with long-term follow-up to demonstrate 
which procedure is best but there is consensus that screening can easily 
be done by measuring urinary albumin-creatinine ratio. Mogensen, et. al., 
1995, Mogensen, 1987 proposed use of the first voided morning urine for 
this purpose. Patients can easily provide this sample and these is little 
water intake during the night or physical activity while asleep, so the urine 
sample is concentrated, allowing for easier detection of albumin. It is 
unlikely that dilution due to high urine volume will result in underestimation 
of albumin excretion (Slight overestimation can not be excluded Gatling 
et. al., 1985, Marshall et.al., 1986, Cowell et. al., 1986, Hutchinson et. al., 1988) i 
Urinary albumin excretion is 30-50% lower during the night, possibly 
due to lower night-time BP and GFR (Mogensen et. al., 1995). An alternate 
to the early morning albumin-creatinine ratio could be overnight or 24 h 
urine collection but these are difficult in practice. Albumin excretion can 
vary by as much as 40% due to natural fluctuations so several tests should 
be done (Mogensen, 1987). Irrespective of the procedure used, two or all 
of the three samples over a 3-6 month period should test positive before 
microalbuminuria is confirmed (Mogensen, 1987). It is generally 
recommended that diabetic patients be screened at least once a year (Viberti 
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et. al., 1994) but some prefer more screening (Mogensen, 1995, Mogensen 
et. al., 1993). Inexpensive immunoturbidimetric assays are not routine in 
many clinical laboratories (Poulsen et. al., 1995). Screening can also be done 
by "Dipstix" but an abnormal result should be confirmed. 
There are several confounding factors for microalbuminuria, such 
as exercise, urinary tract infection, acute illness or cardiac failure, besides 
blood glucose decompensation, but usually these can easily be recognised, 
being detectable at routine clinical and laboratory examinations (Mogensen 
et. al., 1995). Patients with microalbuminuria should be screened more 
frequently and carefully for neuropathy, retinopathy, cardiovascular desease, 
as well as dyslipidemia, becau se they are at high risk of such complications 
Ad. 
(Viberti et. al., 1994, Anon 1994, Jerums et. al., 1994, Consensus development 
conference 1994,Bennetet. al., 1995, Striker 1995). All above recommendations 
propose careful B.P. screening, because BP is often raised in microalbuminuric 
patients. BP should be monitored under standard conditon, after atleast 5 min. 
at rest, with the patient sitting. However, recommendations on the level of 
BP that is to be identified as increased varies with age (Table VI). 24 h 
ambulatory BP may be used when "white coat" hypertension (Especially with 
normoalbuminuria) is suspected (Mogensen, 1995). 
Mogensen et. al., 1995 proposed that BP consistently equal to or 
higher than 140/90 mm Hg below age 60 and higher than 160/90 mn Hg above 
age 60 serves as a minimum indication for intervention. This accords with propos-
als from several hypertension related organisations, although age is not always 
taken into considerations (Anon 1993; Anon 1993; The National High Blood 
pressure Education progrmme 1994). However, this approach may still lead 
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to pharmacological undertreatment of young diabetic microalbuminuria 
patients. In the systolic hypertension in the elderly program (SHEP) study, 
also containing diabetic patients, one inclusion criterion was a systolic BP of 
160 mn Hg or more. Systolic BP was reduced from 170 to 140 mmHg during 
active treatment, which reduced the incidence of stroke significantly (SHEP 
Cooperative Research Group 1991). 
Mogensen et. al., 1995 proposed that treatment aimed at renal dis-
eases should begin when microalbuminuria is detected irrespective of BP, 
especially in young individuals (Bennet et. al., 1995). Early antihypertensive 
treatment, especially with angiotensin-converting enzyme (ACE) inhibitors 
will reduce and/or stabilize microalbuminuria and preserve GFR (Mogensen 
1994). 
It should be useful to monitor GFR (e.g. by single-shot isotope 
decay methods) but this is usually too demanding for routine practice 
(Viberti et. al., 1994). It is also questionable whether this proceure is required, 
because GFR is still normal or supranormal at least in IDDM patients with 
microalbuminuria (Hansen et. al., 1992, Schmitz 1993). Creatinine clearance is 
not a satisfactory marker of the GFR, and collection difficulties, especially 
in diabetic patients, frequently confound interpretation, although not all 
clinicians would agree with the issues (Tsalamandris et. al., 1994, Lane et. al., 
1992). Yearly or Half-yearly serum creatinine measurements would be 
reasonable requirements. 
PREVENTION AND INTERVENTION IN IDDM (Table VI). 
Good blood glucose control will postpone or prevent micro-
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albuminuria and overt renal disease (DCCT 1993). For example the diabetes 
control and complication Trial Research Group DCCT, showed that intensive 
blood glucose control can reduce the incidence of microalbuminuria, 
however, recently (Microalbuminuria Collaborative Study Group, United 
Kingdom) it has been reported that intensive therapy with improved 
glycaemic control for three years had no impact on the progression of 
albuminuria in IDDM patients with microalbuminuria. Usually micro-
albuminuric patients have poorer control than patients with normal albumin 
excretion. However, life style and hypoglycaemic events need to be taken 
into account. Some groups propose glycosylated haemoglobin (HbA,c) level of 
7.0 - 7.5% as the range to aim at (normal HbAjC is 5.5%) but this is 
not easy to achieve and interventions other than tight glucose control must 
be tried (Dahl-Jorgensen et. al., 1994). 
There is general agreement that so called normotensive IDDM 
patients (BP<140/90 mmHg) at age below 60 and <160/90 mmHg above age 
60 should receive antihypertensive treatment with an ACE inhibitor as soon 
as microalbuminuria has been clearly confirmed by several tests and 
provided that the best possible blood glucose control has been obtained for several 
months. Older age should still be considered as a relative modulating 
factor in the indication (Bennett et. al., 1995). The longest follow-up trial in 
young IDDM patients with microalbuminuria has been 8 years (Mathiesen 
et. al., 1995) and long term data on mortality and ESRD (Final end-points) are 
not yet available. ACE inhibitors are beneficial in diabetic patients with 
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overt renal disease (Lewis et. al., 1993) but other agents may also be effective 
(ParvingHHet. al., 1994). 
For hypertensive patients with microalbuminuria, all recommenda-
tions stress tight control of BP. ACE inhibitors are generally preferred because 
their effect on albuminuria may to some extent be independent of their 
influence on systemic BP. ACE inhibitors can be used in combination with 
other drugs (Mogensen et. al., 1993). In general target BP. is 120-130/80-85 
mm Hg, especially in young patients. However, no clear cut long term data 
are currently available to define the exact target. A J-shaped curve (more compli-
cations with Low BP) has not been documented in diabetic patients. 
Microalbuminuria should atleast be stabilized, and ideally it should be 
reduced by 20-30% per year. It is suggested that the antihypertensive 
regimens should be tailored individually. Although some reduction in dietary 
protein intake has also been proposed (Viberti et. al., 1994), there are 
inadequate data to evaluate the long-term consequences of and compliance 
with this approach in microalbuminuric patients. 
During treatment BP and microalbuminuria must be monitored, 
every 1-3 months at first. Monitoring of serum creatinine and serum potassium 
is also crucial, especially during treatment with an ACE inhibitor. However, 
serum potassium rarely increases worryingly in microalbuminuric patients, 
if it does, a low-dose diuretic may be added (Parving H-H et al., 1994). 
This antiproteinuric effect of angiotensin converting enzyme inhibi-
tion may be due either to reduced efferent arteriolar resistance leading to 
diminished glomerular capillary hydraulic pressure or to enhance intrinsic selec-
tivity of the glomerular barrier wall or both. The slow and gradual 
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reduction in microalbuminuria observed during angiotensin converting 
enzyme inhibition suggests a progressive reduction in the permeability of 
the glomerular barrier to protein (Marre et. al., 1988, Mathiesen et. al.. 1991). 
In diabetic rats, converting enzyme inhibition prevents the development 
of albuminuria and restricts mesangial volume expansion and focal 
glomerulosclerosis (Zatz et. al., 1986, Andersen et. al., 1986). This effect 
was associated with a reduction of raised intraglomerular pressure, but in 
another model of experimental chronic renal disease, inhibition of 
angiotensin II attenuated the accumulation of macromolecules in the 
mesangium independently of changes in intraglomerular pressure (Forgo 
et. al., 1988). Inhibition of glomerular basal membrane thickening with 
converting enzyme inhibition in diabetic rats has also been described 
(Cooper et. al., 1989). 
Morelli et. al., 1990 have studied the sieving profile of neutral 
dextran during angiotensin-converting enzyme inibition (Enalapril) in 
16 normotensive insulin-dependent diabetic patients with urinary albumin 
excretion exceeding 50 mg/min (Morelli et. al., 1990) Angiotensin 
converting enzyme inhibition for 90 days significantly reduced the 
fractional dextran clearance and systemic blood pressure . Using a 
heteroporous model of the glomerular barrier and assuming either 
slightly reduced or unchanged transglomerular pressure Morelli et. al., 
1990 suggested that inhibiting converting enzyme enhances barrier size 
selectivity. The potential effect of angiotensin coverting enzyme inhibition 
on charge-selective properties remains to be elucidated. Morphometric 
studies have shown a strong relation between mesangial expansion and 
Table -VII. Prevention and intervention related to NIDDM. 
Document 
St Vincent 
(Viberti et 
al 1994) 
WHO 
(Anon 1994) 
Australia 
(Jerums et 
al1994) 
ADA 
consensus 
(1994) 
National 
Kidney 
Foundaion 
(Bennet et 
al 1995) 
National 
Institute of 
Glycaemic intervention 
o r l l T 
Best possible metabolic 
control, in particular 
primary prevention 
of MA 
DCCT used as 
reference: meticulous 
glycaemic contol 
Intensified glycaemic 
control not proven 
in NIDDM but 
advised 
Optimises 
metabolic 
contral (however 
no results from 
clinical trials 
available in NIDDM) 
No clear data. However, 
best glycaemic control 
possible should 
be goal 
Health (Striker 1995) 
"Normotensive" 
microalbuminuria 
patients, 
ACE inhibition. 
ACE-1 delays pro-
gression to overt 
nephropathy; AHT 
must be tailored 
individually 
Antihypertensive 
treatment of DBP 
increases by 5 mm 
Hg in a year in 
those aged ' 60 yr 
Some AHA, espe-
cially ACE-1 have 
been shown to 
reduce MA, delay 
progression to CON 
and to preserve 
renal function in 
normotensive patients 
Studies show that 
ACE-1 can educe 
MA and may slow 
progression of 
"nephropathy" 
ACE-1 
appropriate 
Insufficient 
data 
"Hypertensive" 
microalbuminuric 
patients 
ACE-1 delayes 
progression to 
overt nephropathy: 
AHT must be tailored 
individually. 
Meticulons control 
of hypertension. 
with particular 
attention to AHA 
that prevents in-
creases in intra-
capillary pressure 
within the kidney 
As in IDDM but 
higher target 
BP( 140/90) in 
elderly 
Any AHA that 
reduce BP may 
be used but some 
some AHA may 
have certain 
advantages 
ACE-1 appropriate 
ACE-1 appropriate 
What to 
monitor 
BP,MA 
albumin 
excretion 
rate.HbA,C, 
RP, creati-
nine, lipids 
As in EDDM 
with more 
emphasis 
on cardio-
vascular 
disease. 
MA,BP, ^ 
C r e a t i n i n e 
potassium 
MA,BP 
MA,BP 
A/C ratio = albumin/creatinine ratio, AC = albumin concentration, UAE = urinary albumin excretion, MA 
= microalbuminuria, AHA = antihypertensive agents, BP = blood pressure, ACE-1 = ACE inhibitor, IIT 
= Intensified insulin treatment, CON = Clinical overt nephropathy. 
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the clinical manifestations of diabetic nephropathy (Maner et. al., 1984) and 
an inverse correlation between the glomerular filtration rate and the 
glomerular filtration surface (Osterby et. al., 1988). A recent morphometric 
study found that insulin-dependent diabetic patients with microalbuminuria 
and hypertension or reduced creatinine clearance, or both, have established abnor-
malities of the glomerular structure including fractional mesangial expansion 
(Chavers et. al., 1989). This clearly indicates that microalbuminuria 
in association with other signs of renal dysfunction can be a marker of 
diabetic glomerulopathy. The authors, however, also reported that microalbuminuria 
without these functional abnormalties is not a marker of underlying glomerular 
lesions (Chavers et. al., 1989) and so must be regarded as a predictor of the 
later development of diabetic nephropathy as originally suggested(Parving 
H-H et, 1982, Viberti et. al., 1982, Mogensen et. al., 1984, Mathiesen et. al., 
1984). 
PREVENTION ANDINTERVENTION IN NIDDM(Table VII) 
There are no formal trials of tight blood glucose control in NIDDM 
but most experts extrapolate from the DCCT 1993, especially in young 
patients and it was also proposed that the best possible control should be 
achieved in patients with NIDDM. 
Antihypertensive treatment in "normotensive" microalbuminuric 
NIDDM has not been studied prospectively in trials on a large number of 
patients. One 5-year intervention study using ACE inhibition (Ravid et. al.. 
1993) in young and lean NIDDM patients, many of whom were normotensive. noted 
that microalbuminuria was reduced, and renal function (scrum 
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creatinine) was preserved. Early ACE inhibition may slow the progression of 
disease in such patients with microalbuminuria" even when BP is "normal". 
In hypertensive microalbuminuric NIDDM patients all agree on the 
need for careful control of BP (Viberti et. al., 1994, Anon 1994, Jerums et. al., 
1994, Consensus development conference 1994, Bennett et. al., 1995, Striker 
et. al., 1995, Anon 1993, Anon 1993. The National High Blood Pressure 
Education Program, 1994). Therapy must be tailored individually but ACE 
inhibition is usually appropriate, though patients with concomitant disease 
may benefit from, say, a calcium antagonist or cardioselective beta-
blocker. Usually these patients also show sodium retention (Wiedmann et. al., 
1991) and even edema, so low doses of diuretic agents may also be 
prescribed. Again microalbuminuria and BP need regular monitoring, 
together with serum creatinine and serum potassium. In elderly people with 
cardiovascular disease, initiation of treatment with an ACE inhibitor in 
moderate doses may result in some detioration of renal function and an 
increase in serum potassium. The recommendations on GFR monitoring 
for IDDM are also relevant to NIDDM. 
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MATERIAL AND METHODS 
A total of 457 normotensive diabetic patients (Type I (n= 197), Type 
II (n=270) were recruited at the out-patient clinic of Endocrinology and Metabolic 
Section of the Department of Medicine, Jawahar Lai Nehru Medical College, 
Hospital, Aligarh Muslim Unversity, Aligarh during January 1988 to August 1989, 
and gave informed consent to participate in the study. 
The diagnosis of diabetes mellitus was established according to 
World Health Organisation (WHO, 1985) criteria. The diagnosis of Type I diabe-
tes mellitus was made on clinical grounds of: 
* Age less then 31 years at the time of diagnosis. 
* Marked osmotic symptoms. 
* Weight loss on presentation. 
* Ketonuria at the time of diagnosis or documented history of diabetic 
ketoacidosis in the past without infection. 
* Insulin dependency. 
C-peptide assay, however, was not performed. 
The Inclusion Criteria for Type -1 - diabetes meilitus in the study were 
* Age less than 40 years. 
* Duration of diabetes - 5 to 15 years, with no evidence of historical, 
clinical or laboratory evidence of non-diabetic renal diseases, systemic, 
cardiac (Rose, 1962), and hepatic diseases. 
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* stablebody mass index (BMI: calculated as weight [kg]/height[m-]. 
* Stable glycaemic index (HbA, < 9%) for preceding three months. 
* Normal blood pressure values on two consecutive examinations (systolic 
< 140 mm Hg; Diastolic < 90 mm Hg as per criteria of Working Group on 
Hypertension, statement on Hypertension, Diabetes Care, 1987). 
* Glomerular Filtration rate(GFR) over 90 ml/min. 
* Microalbuminuria [urinary albumin excretion (UAE) of 30-300 mg/24h] 
on two consecutive visits without evidence of urinary tract infection. 
Diagnosis of Type II diabetes mellitus was made on the clinical ground of 
• 
* Diagnosis after age 35 years. 
* Without the need for insulin therapy in the first year after the diagnosis. 
* No history of ketosis. 
Glucagon test was not performed. 
The Inclusion Criteria for Type-ll diabetes mellitus in the study were : 
* Age ranging between 40-45 years. 
* Known duration of diabetes 5-15 years with no evidence of historical, 
clinical, or laboratory evidence of non-diabetic renal disease, systemic, 
cardiac and hepatic diseases. 
* Stablebody mass index. 
* Stable glycaemic status (HbA,< 9%) for preceding three months. 
* Normal blood pressure values on two consecutive examinations fsystoiic 
< 140 mm Hg; Diastolic < 90 mm Hg). 
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* Glomerular Filtration Rate over 90 ml/min. 
* Micro-albuminuria (UAE of 30-300 mg/24 h) on two consecutive visits 
without evidence of urinary tract infection. 
The patients were not taking any medication other than anti-diabetic 
drugs; all Type -I diabetic patients were taking highly purified insulin 
injections and Type-II subjects on diet, diet combined with oral hypoglycaemic 
agents or with insulin injections. 
Of the 187 Type-I diabetic patients, 49 were excluded because they 
were more than 40 years of age(20), pulmonary tuberculosis( 18), cerebrovascular 
accidents(3), urinary tract infection(8). The remaining 138 patients (aged 23 
to 40 years) were invited to participate and 130 accepted. Of the 130 patients, 
123 submitted three 24 hours urine samples two weeks apart for 
microalbuminuria and 85 patients were selected for the study. The remaining 
38 patients were excluded because of microscopic hematuria (n=9), urinary 
tract infection (n=12) and clinical proteinuria (n=17) from the protocol. 
Of the 270 Type-II diabetic patients, 73 were excluded because they 
were more than 55 years(40) pulmonary tuberculosis(lO), cerebrovascular acci-
dents(8), ischaemic heart diseases(7), and urinary tract infection(8). The remain-
ing 195 patients (aged 43-55 years) were invited to participate and 180 
accepted and submitted three 24 hour urine samples two weeks apart for 
microalbuminuria. Of 180 patients, 116 were selected and remaining 
64 patients were excluded because of microscopic hematuria (n=l5), urinary 
tract infection (n=21) and clinical proteinuria (n=28) from the study protocol. 
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The protocol was approved by the ethical committee of the 
Medicine Department.After a 3-month pretreatment period, the patients were 
randomly allocated to receive either Tab. Enalapril 10 mg daily or placebo in a 
double-blind manner. The placebo tablets were similar in appearance but not 
identical to Enalapril. Randomisation was done using a table of random numbers 
(Shott S, 1990). The follow up period was terminated for each patient, exactly 5-
years after his or her randomisation, and the data were evaluated. 
The patients were followed every 3 to 4 months. On these visits, apart 
from detailed clinical evaluation, fasting blood glucose, HbA,, Serum 
creatinine, serum and urinary electrolytes and albuminuria in 24 h urine 
samples were determined. Blood pressure was measured by mercury 
sphygmomanometers with the patients sitting after a 5 minute rest, the average 
of two determinations were recorded. The diastolic pressure was determined 
at Korotkoff phase V. If systolic blood pressure value of > 145 mmHg, or 
diastolic value of > 95 mm Hg, were found on two consecutive occasions, 
treatment with long-acting Nifedipine was initiated. Fundoscopy was done yearly 
by an ophthalmologist, and presence of diabetic retinopathy was recorded. 
Renal clearance studies and Plasma renin estimation were 
performed at, 6, 12, 24, 36, 48 and 60 months. Urinary urea was also analysed 
during the clearance period to exclude the influence of change in protein intake on 
renal function. Diabetic nephropathy was diagnosed clinically, if persistent 
albuminuria developed in a patient with otherwise normal urine and no 
clinical or laboratory evidence of kidney or urinary tract disease other than 
diabetic glomerulosclerosis. At follow-up, persistent albuminuria was defined 
as a mean UAE exceeding 300 mg/24 h based on atleast six consecutive 
urine collections during the observation period. 
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Analytical Methods 
(I) Determination of Glomerular Filtration Rate (GFR) and Renal 
Plasma flow (RPF): Microanalysis in Medical Biochemistry, J & A 
Churchill, London, 1954, 3rd edition, pp. 223-232. 
The GFR and RPF were estimated by inulin and PAH (Sodium 
aminohippurate). The tests were performed early in the day in a fasting state. The 
subjects were supine during the test, standing up for only a few minute before and 
after voiding. To promote diuresis, subjects were given 200-300 ml of tap water 
to drink every 20 minutes, starting one hour before the experiment, and 
continuing throughout the clearance procedure. Thus a diuresis of about 5-15 ml 
per minute was obtained. Subjects were carefully instructed to empty their 
bladder as completely as possible by pressing once or twice after the 
spontaneous voiding. The loading dose (30 ml) of 10% sterile purified 
inulin was injected intravenously and 3 ml of 20% PAH solution 
subcutaneously. After a 40-60 minute equilibration period, the bladder was 
again emptied by voiding. Thereafter, three carefully - timed urine collections 
were made each lasting from 20 to 40 minutes. Before injection of the 
clearance substance, a venous blood sample was taken, and urine samples 
were collected over a 20-minute period to serve as blanks in the chemical 
determination of inulin and PAH in serum and urine. For the determination 
of inulin, serum was deproteinised with 10% sodium tungstate and 2/3 N sulphuric 
acid. After the addit ion of resorcinol- thiourea solution and 
hydrochloric acid, the samples were placed in a water both at 80°C for 10 minutes. 
Inulin Vk'hich is a polysaccharide of fructose is hydrolysed with hydrochloric acid 
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to free fructose. The fructose is determined by Seliwanoff reaction, in which it 
forms a cherry red color with resorcinoi in the presence 
of hydrochloric acid. 
Inulin clearance was calculated from the average clearance value 
for all collection periods using the equation: 
C. =(U:P) . V/1.73m2 
in ^ •'in 
where (U : P)^ ^ is the urine to plasma inulin concentration ratio and V is the 
urine flow rate in ml/min. The plasma concentration at the mid-point of the 
urine collection was calculated from the plasma inulin contration/time curve. 
Clearance of PAH was used estimating RPF and performed 
simultaneously with determination of GFR. Serum was deproteinised by 
trichloroacetic acid. Serum and urine blanks were determined and substracted 
for the values of clearance samples, and in the determination of inulin. The mean 
coefficient of variation for GFR were 11.7% and 11.9% and for RPF, the 
values were 4.0% and 4.2% before enalapril and placebo treatment among 
subjects of Type I diabetes (P > 0.05). After 5-year of enalapril and placebo 
treatment, the mean coefficient of variation for GFR were 11.8% and 14.6% 
and for RPF, the values were 3.9% and 4.2% (P > 0.05) respectively. Among 
patients of Type II diabetes mallitus, the mean coefficient of variation for 
GFR were 9.8% and 11.7% and for RPF, the values were 2.8% and3.9% (P > 0.05) 
before treatment in the enalapril and placebo-treated group respectively. 
After 5-year of enalapril and placebo treatment, the mean coefficient of 
variation for GFR were 9.9% and 13.4% and for RPF, the values were 2.8% 
and 4.4% (P > 0.05) respectively. 
Ace No. 
78 
(ii) Glycosylated Haemoglobin was estimated by Colorimetric method 
(Fluckigger and Winterhalter, 1976). 
Reagents 
i) 0.1 mol./litre oxalic acid 
63 gms. oxalic acid in 500 ml. of distilled water, 
ii) 40% Trichloroacetic acid (TCA) 
40 gms. of TCA in 100 ml of distilled water, 
iii) 50 millimoles/litre or 0.5 mols/litre Thiobarbituric acid. 
5 mg. Thiobarbituric acid in 100 ml. of distilled water. 
Procedure 
i) Collection of the sample and preparation of the hemolysate 
Four ml. of blood was collected in an EDTA vial and gently mixed. The 
contents were transferred to a centrifuge tube and centrifuged at 3,000 r.p.m. 
to separate the plasma. After the plasma was separated, 1 ml. of RBCs. was 
transferred to a fresh tube, washed with two ml. of 0.9% sodium chloride 
thrice and after final wash, the packed RBCs were mixed with 1.4 ml. of double 
distilled water and 0.4 ml. of glucose, shaken vigorously and centrifuged for 
10 minutes to settle the debris. Haemoglobin concentration of the hemolysate 
was determined by Drabkin solution and concentration adjusted to 10%. 
Two ml. of this hemolysate was used to estimate glycated haemoglobin. 
ii) Estimation of HbA, 
To 2 ml. of hemolysate one ml of oxalic acid (0.1 M) was added. The 
mixture was digested to 100°C in a boiling water bath for 90 minutes and was 
cooled. 
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One ml. of 40% TCA was added and mixed thoroughly with a glass 
rod and centrifuged for seven minutes. Two ml. of clean supernatant was 
transferred to a fresh tube and 0.5 ml. of 0.5 M thiobarbituric acid was 
added, mixed and maintained at 45°C for 30 minutes. 
The released 5-H.M.F. (5-hydroxy methyl furfural) was measured 
at 445 nm against the reagent blank. The absorbance of 10 gm/litre concentration 
of HbAjC corresponds to 0.06 at 443 nm. The relative percent of haemoglobin 
glycated was accordingly calculated. 
iii) Estimation of albumin excretion in urine by Radioimmunoassay 
Urinary albumin excretion was measured in urine collected over 
twenty four hours period by radioimmunoassay. The RIA kit was obtained from 
PHADEBAS, Uppsala, Sweden (detection limit < 0.4 mg/L with 15 \i lit. 
sample volume, no measurable cross reactivity with human IgG, human 
transferrin and B-2 microglobulin and intraassay variability less than 4%). 
Sample Collection 
Twenty four hours urinary samples were collected, while patients 
were in a resting state. Volume of urine was measured and 5 ml of sample was 
stored at -20°C until assayed. 
Principle of the assay 
Urinary albumin was estimated by a double antibody radioimmunoas-
say method. Albumin in the sample competes with a fixed amount of'^^I labelled 
albumin for the binding sites of the specific antibodies. Bound and free 
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albumin were separated by addition of second antibody immunoadsorbant 
followed by centrifugation and decanting. The radioactivity is inversely 
proportional to the quantity of albumin in the sample. 
Calculations 
1. Expressed the count (B) for standards and unknowns as the % (Percentage) 
of the mean count of the 'O-standard' (reference) B . 
B(of the standard of (unknown) 
Percentage of bound activity = 
100 
B 
o 
2. Plotted the percentage values obtained for the standards against the 
concentration on a semi log paper and construct a standard curve. 
3. Read the concentration of the unknown samples from the standard curve. 
If 25 ul of sample is used, the results were multiplied by 2. If 200 ul of 
smaple was used, the result was divided by 4. 
In our laboratory the counting of radioactivity plotting of curve and 
calculation were performed on LKB 1275 computerised minigamma counter using 
RIACALC RM program version 2.57. The individual patient concentration was 
obtained automatically by interpolation on graph using B/B^ on Y axis and standard 
Albumin log concentration on X axis. 
iv) Estimation of Plasma Renin (Radioimmunoassay) 
The RIA kit was supplied by BIODATA - S.P. A. Valeria and distributed 
by ARES SERONO DIAGNOSTIC S.P.A.) and the assay was performed as per 
instruction provided by the supplier of RIA kit. 
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i) Specimen Collection and Handling 
Four ml of blood was collected from patients in the morning in the 
erect posture in pre refrigerated tubes with EDTA-Na^ (2 mg/ml blood). The 
samples were kept in an icebath and in the refrigerator at 4°C. Plasma was 
separated at 4°C at 2,000 rpm in the refrigerated centrifuge. After centrifugation, 
the plasma was kept in ice-bath and stored at -20°C and samples were assayed 
within one month. 
Before the assay, the samples were thawed in icebath avoiding the 
temperature rise of more than 4°C. 
Eventual dilutions were performed by "O" standard, supplied with 
R.I.A. kit(manufacturedby'BIODAlAt S.P.A) Valeria km. 19.600,00012 Guidonia-
Montecelio (RN) and distributed by ARES SERON 0 DIAGNOSTIC • S.P. A). 
No anti-coagulants were used while collecting the samples and 
haemolysed samples were also discarded. 
ii) Principles of the Method 
The kit has been designed for the determination of plasma renin 
activity by Radio-immunoassay of Angiotensin-I. Before the radio-immunoassay, 
sample were incubated, so that renin generates Angiotensin-I in standardized 
conditions. Enzymatic-inhibitor avoids the enzymatic degradation of Angiotensin-
1 during generation stages. 
Plasma generation was performed at pH 6.0 generation buffer, 
utilising the vial supplied with the said reagents, because pH 6.0 method is 
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more reliable for low renin activity samples. 
Angiotensin generation is a linear function in time, so the same 
results are reached, changing generation time, nevertheless the procedure 
foresees 90 minute incubation time at pH 6.0 and guarantees a good precision 
after generation radio-immunoassay is performed. Antigen, whether from stan-
dards or from samples, competes with radioactive tracer (I'^^ Angiotensin) for the 
binding sites on the antibody. 
After incubation the amount of tracer bound to antibody will be 
inversely proportional to the amount of antigen; present in standard samples. 
B/F separation is performed by addition of the double-antibody coupled to mag-
netic particles. The application of field allows the sedimentation of 
immune complex, avoiding the centrifugation step. The main steps of R.I.A. 
are:-
Incubation of reaction mixture for 18-20 hours at 4°C. 
B/F separation by adding double antibody coupled to magnetic particles. 
Decantation of supernatant. 
Counting of the radio-activity in a gamma counter.Plasma renin activity 
is calculated as ng./ml./hour according to the following formula: 
(ng/ml/"37-ng/ml."4")l.ll 
P.R.A. = = ng/ml/hour 
hours 
1.11 - Dilution fraction of sample after addition of P.M.S.F. and generation 
buffer. 
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Hour - Incubation time for angiotensin-I generation. 
- Specific for angiotensin-I is 100%. 
- The sensitivity of method is 0.1% ng/ml. 
- Intra-assay Variability is less than 5% and interassay variability is less 
than 8%. 
The endogenous value of angiotensin-I of plasma samples utilized 
for recovery test is 1.1 ng/ml. 
Normal value for plasma renin activity in healthy subjects (erect 
posture) in the morning ranged from 0.96 to 4.2 ng/ml./hour. 
Serum creatinine was estimated by a direct colorimetric method 
(Heinegard et al, 1973), electrolytes by flame photometry and Serum 
albumin by bromcresol green method (Doumas et al, 1972). Cholesterol and 
triglyceride were measured enzymatically using automated methods (Leet 
et al, 1976, Bucolo et al, 1973). Lipids were measured in serum and 
HDL containing supernatant after precipitation of apo B containing 
lipoproteins with sodium phosphotungstate and Mg Clj (Lopes-Virella et al, 1977). 
LDL-Cholesterol was calculated by the Friedwold et al, 1972). Blood glucose was 
measured by the glucose oxidase method. Protein intake was calculated as 6.25 
times total urinary nitrogen excretion (24 h urinary 
nitrogen excretion plus non-urea nitrogen) excretion estimated to 2g/day per 
patient (Matoni et al, 1985, Isakason et al, 1982). 
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Statistical Analysis 
All data are expressed as means (±SD) and ranges. Significance was 
defined as p<0.05. To test for adequate randomisation, the enalapril and the 
placebo groups were compared with respect to mean age, duration of diabetes, 
as well as values of albuminuria, serum creatinine, GFR, HbA, and systolic 
and diastolic blood pressure using pooled variance. Paired and unpaired student's 
't' tests were used for comparisons within and between the groups. The best 
polynomial fit for the time course of uninary albumin excretion, blood 
pressure, glomerular filtration rate and renal plasma flow was sought with 
analysis of variance. The best fit was linear in all cases, and the slope of a fitted 
line to the data was measured by the regression coefficient estimated by least 
squares. The individual slopes of the two groups were compared by student's 
test. All patient data were included in the analysis, and correlations were 
sought by stepwise multiple linear regression analysis using urinary albumin 
excretion as dependent variable and systolic and diastolic blood pressure, 
glycosylated haemoglobin, glomerular filtration rate and renal plasma flow as 
independent variables. In this analysis, log transformed values of urinary albumin 
excretion were used. A 'p' value of less than 0.05 was considered significant. 
Table-VIII. Clinical and Laboratory data at baseline in normotensive Typ 
diabetic patients with persistent microalbuminuria. 
Variable Placebo Enalapril 
Patients, n 
Men/women, n/n 
Mean age, y 
Age at diagnosis, y 
Duration of diabetes, y 
BMI, Kg/m^ 
FPG, mmol/L 
HbA,.% 
UAE mg/24 h 
GFRml.min.'1.73m2 
Mean Systolic B.P.(mni Hg) 
Mean diastolic B.P.(mni Hg) 
Energy intake, Kcal/24h 
Protein intake, g/24h 
Insulin dose, IU/Kg/24h 
No. with retinopathy, none/ 
Background/Proliferative 
36 
19/17 
31.7*3.8(25 to 40) 
21.0:t4.0(12to28) 
10.1±2.2(5to 15) 
22.6±0.S(19.9to24.6) 
4.7±0.7(3.7to6.7) 
8.3±0.5(7.2to8.9) 
105±53.4(39to250) 
130±l5.5(97tol55) 
132±3.6(126tol38) 
82*3.1(76 to 88) 
1786±139.7(1500 to 2000) 
75*6.3(65 to 90) 
0.8±0.2(0,6to 1.5) 
12/24/0 
37 
19/18 
31.3±3.2(27to38) 
20.7±3.7913to28) 
10.6±2.8(6to 15) 
22.5±1.0(19.7to24.5) 
5.3±0.8(4.3 to6.9) 
8.0±0.7(6.7to8.9) 
98±50.6(33to225) 
131±i5.3(95to 147) 
130±3.9(120tol38) 
80±3.3(72to86) 
1776±149.8(1500to2000) 
75±7.1(65to90) 
0.8±0.2(0.6to 1.5) 
13/24/0 
* Data are mean ±SD (range). BMI=bodymass index, FBS=Fasting plasi 
glucose, HbA,=glycosylated hemoglobin, UAE=Urinary albumin excretion 
Table-IX. Clinical and Laboratory data at baseline in normotensive Type 
diabetic patients with persistent microalbuminuria. 
Variable Placebo Enalapril 
Patients, n 
Men/women, n/n 
Mean age. y 
Age at diagnosis, y 
Duration of diabetes, y 
BMI. Kg/m= 
FPG. mmol/L 
HbA,.% 
UAE mg/24 h 
GFRml.min.'1.73m^ 
Mean Systolic B.P.(nim Hg) 
Mean diastolic B.P.(mni Hg) 
Energy intake. Kcal/24h 
Protein intake. g/24h 
No. with retinopathy, none/ 
Background/Proliferative 
51 
30/21 
50.3±2.1(45to55) 
41.0±2.9(36to46) 
9.3±2.4(5to 15) 
23.2±0.7(21.5to24.4) 
4.6i:0.9(4.0to6.7) 
8.1±0.5(6.5 to8.8) 
86±44.5(30to 190) 
124±14.6(92to 149) 
132±3.9(120to 138) 
82±3.2(74to86) 
1690±117,6(1500 to 1800) 
67±8.8(46to83) 
23/28/0 
Therapy. 
Diet alone 
Oral agents 
Insulin 
12 
31 
8 
52 
30/22 
49.8±3.0(43to58) 
40.5±2.3(36to44) 
9.2±2.4(5to 15) 
22.9±0.8(21.3to24.9) 
4.8±0.7(3.7to6.9) 
8.0±0.6(6.8to8.9) 
90±47.5(32tol80) 
124±12.2(95to 148) 
132±3.9(120to 138) 
81±3.8(70to88) 
1694±1 16.7(1500 to 1800) 
67±8.6(46to83) 
25/27/0 
14 
2Q 
* Data are mean ±SD (range). BMI=bodymass index, FBS=Fasting plasn 
glucose, HbA,=glycosylated hemoglobin. UAE=Urinar>' albumin excretion 
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OBSERVATION 
Of 85 patients of Type I diabetes mellitus, 2 taking enalapril and 5 
taking placebo left the study during the Ilnd year. Five patients (3 taking 
enalapril and 2 taking placebo) developed persistent disturbing cough, and the 
treatment was discontinued. The final analysis was therefore done on 73 
patients, of whom 37 received enalapril and 36 received placebo. Age. male/ 
female ratio, duration of diabetes, and the other baseline data of the two groups 
are shown in Tab lev i i i .No statistically significant differences existed 
between the initial characteristics of the enalapril and the placebo group. 
Among 116 patients of Type-II diabetes mellitus, I taking enalapril 
and 2 taking placebo left the study during the first year. Six patients (5 taking 
enalapril and one taking placebo) developed a disturbing cough, and the 
treatment was discontinued. Four patients (2 on enalapril and 2 on placebo 
were lost to follow-up during the Ilnd and Ilird years. The final analysis 
was therefore done on 103 patients, of whom 52 received enalapril and 51 
received placebo. Age, male/female ratio, duration of diabetes, and the 
other baseline data of the two groups are shown in Table-ix.No statistically 
significant differences existed between the initial characteristics of the enalapril 
and the placebo group. 
Albumin Excretion Rates 
During the first year of treatment among subjects of Type-1 
diabetes mellitus, the urinary albumin excretion (UAE) in the enalapril group 
Fig. 2. Albuminuria during 5-year follow-up in Type i diabetics treated with 
enalapril or placebo. Each point on the curve represents the annual 
average of 3 to 4 determinations per patient. Data are mena ±SD. less 
proteinuria occured in the enalapril group compared with placebo after 
the second year (P<0.02 from second to fifth years). 
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decreased from an initial mean of 98mg/24h to an annual mean of 49 mg/24h. 
Subsequently, a minimal but steady increase occured in mean daily albumin 
excretion of these patients, with a third year mean of 54 mg/24h. In the fourth 
and fifth year of enalapril treatment, the mean daily albumin excretions were 
67 mg/24 h and 71 mg/24h respectively. In three patients, albuminuria exceeded 
300 mg/24 h. In contrast, among the placebo-treated patients, a steady gradual 
increase occcured in mean daily albuminuria. The initial albumin value was 
105 mg/24 h, the first year mean was 113 mg/24h, the third year mean was 
172 mg/24h and the fourth and fifth-year means were 209 mg/24h and 
230 mg/24h respectively. Albumin values were greater than 300mg/24h in 11 
patients. The difference between the mean values of daily albuminuria in the 
two groups became statistically significant after the first year. However, the 
difference in the rate of change in proteinuria from baseline was statistically 
significant at the end of first year (P<0.05). These data are shown in Fig. 2 
and are numerically detailed in the Appendix table X . If the development of 
overt proteinuria (> 300 mg/24h) is considered clinically important, the risk 
for developing this degree of proteinuria within 5-years of follow-up was 
11/36 (30.5%) in the placebo-group compared with 3/37 (8.1%) in the 
enalapril group. Therefore, enalapril treatment resulted in as absolute risk 
reduction of 22.4 percentage points for the development of overt proteinuria 
for a 5-year period (P<0.01). 
Among subjects of Type II diabetes mellitus, during the first-year 
of treatment, the urinary albumin excretion in the enalapril group decreased 
from an initial mean of 90 mg/24h to an annual mean of 80 mg/24h. Subsequently 
a steady decrease occured in mean daily albumin excretion of these patients. 
Fig. 3. Albuminuria during 5-year follow-up in Type II diabetics treated with 
enalapril or placebo. Each point on the curve represents the annual 
average of 3 to 4 determinations per patient. Data are mean ±SD. Less 
proteinuria occured in the enalapril group compared with placebo after 
the second year (P<0.02, 0.005, < 0.01 and <0.01 for second, third, 
fourth & fifth year respectively. 
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with a third year mean of 58 mg/24h. In the fourth and fifth-year of enalapril 
treatment, the mean daily albumin excretions were 55 mg/24h and 48 mg/24h 
respectively. In four patients, albuminuria exceeded 300 mg/24h. In contrast, 
among the placebo treated patients, the initial albumin value was 86 mg/24h 
and the first-year mean was 87 mg/24h and the second-year mean was 
106 mg/24h. The third, fourth and fifth year mean values were 130 mg/24h, 
151 mg/24h and 169 mg/24h respectively. Albumin values were greater than 
300 mg/24h in 12 patients. The difference between the mean values of daily 
albuminuria in the two groups also became statistically significant after the 
first years, however, the difference in the rate of change in proteinuria 
from baseline was statistically significant at the end of first year (p<0.05). 
These data are shown in Fig. 3 and are numerically detailed in the Appendix 
Table XI . The risk for developing clinical proteinuria (> 300 mg/24h) within 
5-year of follow-up was 12/51 (23.5%) in the placebo group compared with 4/52 
(7.7%) in the enalapril group indicating an absolute risk reduction of 15.8 
percentage points for the development of clinical proteinuria for a 5-year 
period (P<0.01). 
Renal Function Tests 
Renal function expressed as glomerular filtration rate (GFR) and 
renal plasma flow (RPF) remained unchanged in both groups during the study 
period among subjects of Type I diabetes mellitus (Table X ). In the enalapril group 
a non-significant decrease in GFR from 13 1±15.3 ml.min.' 1.73 m- to 130±15.2 
ml.min' 1.73 m ,^ 129±15.2 ml.min' 1.73m2, 127±15.3 ml.min.' 1.73 m- and 
126±15.0 ml.min' 1.73m^ at second, third, fourth and tlfth year respectively 
Fig. 4. Time course of glomerular filtration rate during 5-year follow-up in 
Type I diabetics treated with enalapril or placebo. Data are mean ±SD. 
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were recorded Fig. 4 (P > 0.05). In the placebo group also the GFR decreased 
insignificantly from 130±15.5 ml.min.-' 1.73 m^ to 126±16.5 ml.min' 17.3 m^ 
123±18.8 ml.min.-' 1.73 m ,^ 123±18.7 ml.min.' 1.73 m^  and 121±20.1 ml.min' 
1.73 m^ at second, third, fourth and fifth year respectively Fig. 4. An 
insignificant rise in RPF from 573±22.69 m,.min' 1.73 m^  to a fourth and 
fifth-year value of 581±22.4 ml.min'l,73m2 and 583±22.8 ml.min' 1.73 m^  
were noted in the enalapril treated patients, but not in the placebo group 
where in RPF decreased insignificantly from 577±23.49 ml.min.' 1.73 m^  
to a fourth and fifth year value of 572±23.7 ml.min.' 173 m^  and 570±24.0 
ml.min.' 1.73 m^  respectively Fig. 5. The changes in GFR and RPF produced 
by enalapril in individual patient were inconsistent and variable. 
Among patients of Type II diabetes mellitus also, both GFR and 
RPF were remained unchanged in both enalapril and placebo treated groups 
(Table XI , Fig. 6 and Fig. 7). In the enalapril treated patients, a non-
significant decrease in GFR from 124±12.2 ml.min.' 173 m^  to I21±12.0 
ml.min.' 173 m^ 129±12.0 ml.min.' 1.73 m^ 120±12.2 ml.min.' 1.73 m- and 
119±12.0 ml.min.' 1.73 m^  at second, third, fourth and fifth year respectively 
were recorded (P > 0.05). In the placebo-treated patients also, an insignificant 
decrease in GFR from 124±14.6 ml.min.' 173m2 to 121±14.9 ml.min.' 173m^ 
120±15.3 ml.min.-' 173m2, 119±15.5 ml.min.' n3m^ and 119±15.5 ml.min. ' 
173m^at second, third, fourth and fifth year respectively (P>0.05). The initial 
RPF increased insignificantly from 580±16.5 ml.min." 1.73 m^  to a fourth and 
fifth year value of 585±15.7 ml.min.' 1.73 m^  and 585±165. ml.min.' 1.73 m^  
respectively in the enalapril treated patients, but not in the placebo group, 
where RPF decreased insignificantly from 566±22.3 ml.min.' 1.73 m^  to a 
Fig. 8. Systolic and diastolic blood pressure values during 5-year follow-up in 
Type I diabetics treated with enalapril or placebo. Values are mean ±SD. 
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fourth and fifth year value of 560±23.7 ml.min.' 1.73 m^ and 558±23.6 
ml.min."' 1.73 m^ respectively. The changes in GFR and RPF produced by 
enalapril in individual patient of this group were also inconsistent and variable. 
Blood Pressure 
The mean systolic and diastolic blood pressure in the enalapril-
treated patients of Type I diabetes mellitus remained statistically unchanged 
(Table X ). The initial mean was 130/80 mm Hg and the annual mean was 
130/80 mm Hg, and a fourth and fifth-year means were 130/80 mm Hg and 
129/83 mm Hg respectiely. In three patients in this group, systolic blood 
pressure greater than 145 mm Hg or diastolic values greater than 95 mm Hg 
were recorded, and treatment with a long-acting nifedipine 10 mg to 20 mg 
twice daily was added. In the placebo-treated group, the annual mean systolic 
blood pressure increase of 1 to 2 mm Hg and an annual mean diastolic blood 
pressure increase of 1 to 3 mm Hg were recorded of the 36 patients in the 
placebo-treated group, elevated blood pressure values greater than 145/95 
mm Hg was recorded in 11 patients and they were trated by long-acting 
nifedipine. The mean systolic and diastolic blood pressure values are shown 
in Fig. 8, Table X . 
In patients of Type II diabetes mellitus also, the mean systolic and 
diastolic blood pressure in the enalapril and placebo-treated subjects remained 
statistically unchanged (Table XI ). In the enalapril group. The initial mean was 
132/81 mm Hg, the annual mean was 133/81 mm Hg and a fourth and fifth year 
mean were 130/90 mm Hg and 134/80 mm Hg respectively. In four patients of 
this groups, systolic blood pressure of greater than 145 mm Hg or diastolic 
Fig. 9. Systolic and diastolic blood pressure values during 5-year follow-up in 
Type II diabetics treated with enalapril or placebo. Upper part of the 
figure illustrates systolic blood pressure and lower part diastolic blood 
pressure. Values are mean ±SD. 
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Table Xll. Baseline and 5 year follow-up values in Type 1 diabetic patients with 
microalbuminuria receiving enalapril or placebo. 
BMI, Kg/M2 
Enalapril Group 
Placebo Group 
Serum Potassium(nieq/L) 
Enalapril Group 
Placebo Group 
Serum Sodium (meq/L) 
Enalapril Group 
Placebo Group 
Serum Creatinine (mg%) 
Enalapril Group 
Placebo Group 
Serum Cholesterol(mg%) 
Enalapril Group 
Placebo Group 
Serum Triglyceride (mg%) 
Enalapril Group 
Placebo 
LDL-cholesterol (mg%) 
Enalapril Group 
Placebo Group 
VLDL-Cholesterol (mg%) 
Enalapril Group 
Placebo Group 
HDL-Cholesterol (mg%) 
Enalapril Group 
Placebo Group 
Uninary Urea (g/24h) 
Enalapril Group 
Placebo Group 
Plasma Renin (ng/ml/h) 
Enalapril Group 
Placebo Group 
Baseline 
22.54+1.04 
22.57+0.81 
3.73+0.16 
3.75+0.19 
136.7+1.56 
136.9+1.71 
0.72+0.23 
0.76+0.14 
226.05+29.73 
232.44+34.80 
137.41+.25.77 
135.25+32.89 
153.76+30.85 
168.05+35.76 
27.62+5.51 
26.67+6.61 
45.43+7.98 
39.75+6.19 
19.17+0.94 
20.73+1.14 
3.01+0.69 
2.83+0.85 
5 Year Follow-Up 
23.04+1.0 
23.08+0 97 
4.05+0.03 
3.74+0.17 
136.4+0.21 
136.5+0.16 
0.70+0.1 
0.85+0.25 
227.54+2901 
230.0+34.61 
135.32+27.41 
134.14+24.95 * 
156.0+29.70 
164.14+31.31 
26.95+5.69 
26.64±5 18 
44.22+7.59 
39.56+6.58 
19.19+0.75 
20.63+0.88 
7.93+1.71 
2.81+0.84 
90 
blood pressure greater than 95 mm Hg were recorded and treatment with a 
long-acting nifedipine 10 mg to 20 mg twice a day was added of the 51 patients 
in the placebo treated group, the annual mean systolic blood pressure increase 
of 1 to 3 mm Hg and an annual mean diastolic blood pressure increase of 1 to 
2 mm Hg were recorded. Elevated blood pressure values of greater than 
145/95 mm Hg was recorded in 12 patients and were treated by long-acting 
nifedipine. The mean systolic and diastolic blood pressure values are shown in 
Fig. 9, Table XI . 
Laboratory Values 
Serum potassium concentrations rose from 3.73±0.16 meq/L to 
4.05±0.03 meq/L during treatment with enalapril in patients of Type I diabetes 
mellitus, but this did not lead to change of treatment in any patient. 
The serum potassium concentrations in placebo group, however 
remained statistically unchanged (Table XII ). The plasma renin activity 
increased significantly in the enalapril group from 3.01±0.69 ng/ml/h to 
7.93±1.71 ng/ml/h than in the placebo-treated patients (P < 0.002) indicating 
substantial inhibition of angiotensin converting enzyme activity (Table XII ). 
The control of glucose levels was stable as judged by mean fasting plasma 
glucose and glycosylated haemoglobin values during the 5 years in both 
enalapril and placebo treated patients (Table X ). No statistically significant 
difference was observed in the body mass index urinary urea excretion and 
serum lipid concentrations in the enalapril and placebo treated patients of 
Type I diabetes mellitus (Table XII ). Stepwise multiple regression analysis 
between UAE, systolic and diastolic blood pressure, fasting plasma glucose. 
TableXlll- Multiple correlation coefficients between DAE, systolic (sBP) 
and diastolic blood pressure (dBP), HBA,, GFR and RPF in 
Type-1 diabetic patients over 5-year follow-up. 
Variab les 
Before enah 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
5-vear 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
after 
ipril 
ena 
Before placebo 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
5-vear 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
after 
Corrdation 
treatment 
-0.007 
-0.116 
0.140 
0.119 
-0.197 
lapril treatment 
0.265 
0.373 
0.140 
-0.063 
-0.112 
treatment 
-0.076 
0.002 
0.172 
0.180 
0.149 
placebo-treatment 
0.785 
0.259 
-0.029 
-0.344 
0.109 
Regression 
0.352 
-2.279 
7.255 
0.349 
-0.294 
0.849 
6.349 
13.806 
-1.406 
0.754 
-1.221 
3.642 
19,946 
0.855 
0.327 
2.148 
4.763 
9.365 
0.264 
0.368 
S.E. 
regression 
2.379 
2.691 
14.045 
0.604 
0.389 
2.104 
3.063 
24.312 
1.084 
0.768 
3.489 
4.002 
20.708 
0.875 
0.539 
1.492 
4.447 
39.211 
0.076 
0.516 
+values 
0.148 
-0.847 
0.517 
0.579 
0.755 
0.404 
2.073 
0.568 
-1.297 
0.981 
-0.350 
0.910 
0.963 
0.975 
0.607 
1.439 
1.071 
0.239 
0.349 
0.713 
UAE=dependent variable, sBP, dBP. HbA,, GFR and RPF are independent variables. 
Table XIV. Baseline and 5 year follow-up values in Type II diabetic patients with 
microalbuminuria receiving enalapril or placebo. 
BMI, Kg/M2 
Enalapril Group 
Placebo Group 
Serum Potassium(meq/L) 
Enalapril Group 
Placebo Group 
Serum Sodium (meq/L) 
Enalapril Group 
Placebo Group 
Serum Creatinine (mg%) 
Enalapril Group 
Placebo Group 
Serum Cholesterol(mg%) 
Enalapril Group 
Placebo Group 
Serum Triglyceride (mg%) 
Enalapril Group 
Placebo 
LDL-cholesterol (mg%) 
Enalapril Group 
Placebo Group 
VLDL-Cholesterol (mg%) 
Enalapril Group 
Placebo Group 
HDL-Cholesterol (mg%) 
Enalapril Group 
Placebo Group 
Urinary Urea (g/24h) 
Enalapril Group 
Placdjo Group 
Plasma Renin (ng/ml/h) 
Enalapril Group 
Placebo Group 
Baseline 
22.69±0.82 
23.24±0.69 
3.69±0.17 
3.73±0.18 
137±1.78 
137±1.79 
0.72±0.14 
0.71±0.09 
239.63±34.63 
227.96±43.44 
144.09±39.24 
140.94±31.53 
172.52±35.49 
165.53±32.43 
28.48±7.88 
27.76±6.32 
40.17±7.36 
41.51±7.34 
18.49±0.76 
18.49±0.76 
2.65±0.66 
2.63±0.72 
5 Year Follow-Up 
22.90±0 82 
23,30±0 62 
4.15±0.15 
3.72±0 14 
137±1 21 
138±1 26 
0.74±0 11 
0.71±0 14 
238.46±32 89 
232.27±32 53 
143.08±38.41 
141.06±31 76 
172.85±27 69 
163.02±29 50 
28,25±7 61 
28.12±6 79 
40.19±7 45 
41.92±6.42 
18 47±0 76 
18.47±0 67 
7.27±2.13 
2.64±0 58 
TableXV- Multiple correlation coefficients between UAE, systolic (SBP) 
and diastolic blood pressure (dBP), HBAl, GFR and RPF in 
Type-II diabetic patients over 5-year follow-up. 
Variables 
Before 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
5-vear 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
Before 
UAE 
sBP 
dBP 
PfbA, 
GFR 
RPF 
5-vear 
UAE 
sBP 
dBP 
HbA, 
GFR 
RPF 
enalapri 
after 
Corrdation 
1 treatment 
0.043 
0.118 
-0.017 
0.073 
0.041 
enalapri! treatment 
placebo 
after 
0.039 
0.116 
-0.139 
0.274 
-0.029 
treatment 
0.169 
0.124 
0.344 
-0.083 
0.027 
placebo-treatment 
0.603 
0.689 
0.053 
-0.304 
0.253 
Regression 
-0.437 
1.787 
-2.849 
0.169 
0.114 
-0.224 
2.018 
-24.405 
1.606 
-0.452 
2.041 
-0.826 
35.251 
-0.062 
0.131 
10.364 
5.759 
-26.416 
-0.793 
0.540 
S.E. 
regression 
1.965 
2.365 
12.718 
0.593 
0.457 
1.651 
3.128 
26.708 
1.054 
0.781 
2.564 
3.114 
14.835 
0.444 
0.304 
5.152 
3.320 
25.601 
0.761 
0.481 
+values 
-0.223 
0.755 
-0.224 
0.285 
0.248 
-0.136 
0.674 
-0.914 
1.524 
-0.579 
0.796 
-0.265 
2.376 
-0.139 
0.429 
2.000 
1.734 
-1.032 
-1.042 
1.123 
UAE=dependent variable, sBP, dBP, HbA,, GFR and RPF are independent variables 
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HbA , GFR and RPF showed that reduction in albuminuria was not 
correlated with the above variables (Table Xlll) among Type 1-diabetic patients. 
No statistically significant difference was observed in the body mass index, 
urinary urea excretion and serum lipid concentrations in the enalapril and 
placebo treated patients of Type I diabetes mellitus (Table XIII). 
In patients of Type II diabetes mellitus also, the serum potassium 
concentrations rose from 3.69±0.17 meq/L to 4.15±0.15 meq/L during 
treatment with enalapril, but this did not lead to change of treatment in any 
patient. The serum potassium concentrations in placebo group remained 
statisticallyunchanged (Table XIV). A statistically significant increase in plasma 
renin activity was observed in the enalapril group from 2.65±0.66 ng/ml/h 
to 7.27±2.13 ng/ml/h than in the placebo-treated patients (p<0.002), 
indicating substantial inhibition of angiotensin coverting enzyme activity 
(Table XIV). The glycaemic status was stable in both the groups as judged 
by mean fasting plasma glucose and glycosylated haemoglobin concentrations 
(Table XI). Stepwise multiple regression analysis between UAE, systolic and 
diastolic blood pressure, fasting plasma glucose, HBA,, GFR and RPF showed 
that reduction in albuminuria was not correlated with the above variables 
(Table XV) among Type II diabetic patients. No statisticaly significant 
difference was observed in the body mass index and serum lipid concentrations 
and urinary urea excretion was stable in both groups during the study 
(Table XIV). 
92 
DISCUSSION 
The 5-year, randomized, double-blind, placebo-controlled trial 
shows the long-term antiproteinuric effect of enalapril in normotensive 
diabetic patients (Type I (n=73). Type II (n=103) and microalbuminuria 
compared with placebo-treated patients, the enalapril treated subjects also had 
effective protection of their kidney function in both Type I and Type II diabetes 
mellitus. The angiotensin-converting enzyme inhibition with enalapril 
reduced urinary albumin excretion while leaving systemic blood pressure and 
the glomerular filtration rate essentially unchanged. The difference in the 
enalapril and the placebo-treated patients is important in view of the careful 
control of blood pressure in both groups of Type I and Type II diabetes 
mellitus by using long-acting calcium-channel blocker, nifedipine when 
any increase of either systolic or diastolic blood pressure occured beyond 
strictly defined limits. More important, only 3 out of 37 (0.1%) patients 
of Type I diabetes mellitus receiving enalapril progressed to diabetic 
nephropathy whereas 11 out of 36 (30.6%) placebo-treated patients of 
Type I diabetes mellitus progressed to diabetic nephropathy. Among patients 
of Type II diabetes mellitus, only 4 out of 52(7.7%) patients receiving 
enalapril progressed to diabetic nephropathy whereas 12 out of 51(23.5%) 
placebo-treated patients progressed to diabetic nephropathy. Besides 6 of 11 
patients of placebo treated Type I diabetes and 8 of 12 placebo-treated 
patients of Type II diabetes mellitus had evidence of coronary heart disease 
(Ross, 1962). 
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Renal protective effect by angiotensin-converting inhibitors (albu-
min excretion and preservation of renal function) have been reported in 
hypertensive and in normotensive patients with diabetic nephropathy 
(Mogensen 1982, Parving H-H et al 1983, Parving H-H et al 1987, Ravid 
et al 1992, Parving H-H et al 1988, Bjorck et al 1992, Ueda et al 1990, 
Mathesen et al 1991, Marre et al 1988), and also in non-diabetic patients 
with proteinuria (Ferder et al 1990, Apperloo et al 1991). However, most 
of the studies were short-term, comprised small number of patients and 
were mainly concerned with Type I diabetes mellitus. There is general 
agreement that so-called normotensive Type I diabetic patients (BP <140/90 
mm Hg at age below 60 and <160/90 mm Hg above age 60) should 
receive antihypertensive treatment with an angiotensin-converting enzyme 
inhibitor as soon as microalbuminuria has been confirmed by several tests 
and provided that the best possible glycaemic control has been obtained for 
several months. The longest follow-up trial in young Type I diabetic patients 
with microalbuminuria has been 8 years (Mathiesen et al 1995) and long 
term data on mortality and end-stage renal disease (final end-points) are not 
yet available. 
All recommendations stress tight control of blood pressure for 
hypertensive patients with microalbuminuria. Angiotensin converting enzyme 
inhibitors are preferred in view of their independent influence on systemic 
blood pressure in reducing albuminuria. The target blood pressure is 120-130/ 
80-85 mm Hg, especially in young patients and it can be used in combination 
with other drugs ( Mogensen et al, 1993). 
94 
Antihypertensive treatment has not been studied in trials on large 
number of patients in "normotensive" microalbuminuric Type II diabetic 
patients. Recently Ravidetal, 1993 in a randomized, placebo-controlled, double-
blind study on 94 patients with Type II diabetes who were young and 
lean, have reported that the institution of Angiotensin-converting enzyme 
inhibition during early stages of diabetic nephropathy results in long-term 
stabilisation of plasma creatinine levels and of the degree of loss of albumin. 
However, the assessment of evolution of nephropathy was done by using 
reciprocal serum creatinine. Early angiotensin-converting enzyme inhibition 
may slow the progression of renal disease in such pat ients with 
microalbuminuria, even when blood pressure is "normal". 
In hypertensive microalbuminuric Type II patients, all agree on the 
need for careful control of blood pressure (Viberti et al, 1994, Anon, 1994, 
Jerums et al, 1994, Consensus development conference, 1994, Bennet et al, 
1995, Striker, 1995, Anon, 1993, The National High Blood Pressure 
Education Program Working Group, 1994). Angiotensin-converting enzvme 
inhibition is appropriate, though patients with concomitant disease may 
benefit from say, a calcium channel blocker may also be prescribed as some 
of these patients may also show sodium retention (Wiseman et al 1991) and 
even edema. The recommendations on glomerular filtration rate monitoring 
for Type I diabets are also relevant to Type II diabetes mellitus. 
The natural history of nephropathy in Type I and Type II diabetes 
mellitus in India have not been reported and no data have been published on 
the long-term intervention and the possibility of a true alteration of the natural 
course of the disease. Allawi et al, 1988 have reported that a high proportion 
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of Indian patients with Type II diabetes mellitus, urinary albumin excretion 
is abnormally increased and significantly higher than that in comparable 
Europe patients, however, no study is available among Indian subjects with 
different ethnic background. 
In the present study, the decrease in albuminuria from an initial 
mean of 98 mg/24h to a first year mean of 49 mg/24h, was followed by a slow 
increase toward a fifth-year average of 71 mg/24h in the enalapril teated 
patients of Type-I diabetes mellitus. among the 37 patients treated with 
enalapril, only 3 patients had albuminuria that increased beyond the 300 
mg/24h threshold. In contract, the mean daily albumin excretion of the 
patients who received placebo, increased progressively from year to year. The 
fifth year average was 119% greater than the initial value (P<0.001) , with 11 
patients who had 24-hour albumin excretion values greater than 300 mg. 
These differences could not be attributed to the differences in body mass 
index, glycaemic control, or blood pressure values, which were very similar in 
both groups throughout the study period. We emphasize that serum cholesterol 
and triglyceride concentrations, protein intake also remained nearly identical 
in the two groups during the five years. Energy, sodium and protein restriction 
was not applied in our study. Treatment with prostaglandin inhibitor was 
avoided. Stepwise multiple regression analysis between urinary albumin exretion, 
systolic and diastolic blood pressure, glomerular filtration rate, fasting blood 
glucose and HbA, showed that reduction in albuminuria was not correlated 
with the above variables (Table XliI). We did renal function using inulin and 
PAH for estimation of glomerular filtration rate and renal function 
( Mogensen, 1971). 
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Similarly in patients of Type II diabetes mellitus also, the decrease 
in albuminuria from an initial mean of 90 mg/24h was followed to a tlfth-year 
average of 48 mg/24h in the enalapril-treated patients, while in patients, 
albuminuria increased beyond the 300 mg/24 h threshold. In contrast, the 
mean daily albuminuria of patients who received placebo, progressed from 
year to year. The fifth-year average was 97% greater than the initial value 
(P<0.001), with 12 patients who had 24 hour albumin excretion values greater 
than 300 mg/24 h. These differences could not be attributed to the differences 
in the body mass index, glycaemic control, or blood pressure values, which were 
very similar in both groups throughout the study period. Further, the serum 
cholesterol and triglyceride concentrations and protein intake also remained 
nearly identical in the two groups during the five years. Energy intake, sodium and 
protein restriction was not applied and treatment with prostaglandin inhibitor was 
avoided. Stepwise multiple regression analysis between urinary albumin 
exretion, systolic and diastolic blood pressure, glomerular filtration rate, 
renal plasma flow, fasting blood glucose and HbA, showed that reduction in 
albuminuria was not correlated with the above variables (Table XV ). 
The mechanism by which antihypertensive drugs reduce albuminuria 
are not totally understood. The blood pressure is very important for renal 
function in diabetic nephropathy. Treatment of hypertension has been 
repeatedly documented as beneficial in reducing the rate of deterioration in 
kidney function when nephropathy is present (Parving H-H et al 1987, The 
working Group on Hypertension in Diabetes mellitus, 1987). The question 
is whether antihypertensive drugs differ in this regard. Since angiotensin II 
can increase intraglomerular pressure (Blantz et al, 1976), lowering 
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angiotensin II seems a logical way to overcome the renal consequences of 
diabetes (Bjorek et al 1986), provided that an increased filtration pressure 
plays a role in the^pathogenesis of diabetic nephropathy. From a theoritical 
standpoint, angiotensin converting enzyme inhibitors might offer an advantage. 
In experimental non-diabetic renal disease, the effects of different 
antihypertensive drugs on the kidney have been tested. Raij et al, 1985 
investigated rats with spontaneous hypertension and surgical reduction of renal 
mass, who received no treatment, a combination of hydralazine, reserpine and 
hydrochlorthiazide or the angiotensin converting enzyme inhibitor, enalapril. 
Both drug regimens were effective in reducing blood pressure, but enalapril 
was more efficient in preventing an increase in albuminuria and in mesangial 
injury score. These findings have been verified by Anderson et al, 1986 in an 
experiment with rats with reduced renal mass. In addition, they found that 
enalapril treatment, in contrast to the triple-drug treatment, normalized 
intraglomerular pressure. 
The renal effects of ACE inhibition have also been investigated in 
diabetic animals. Zatz et al, 1986 found that when enalapril treatment 
reduced blood pressure in normotensive, insulin-treated, streptozotocin-
induced diabetic rats, the rise in albumin excretion seen in diabetic controls 
was completely prevented. Enalapril treatment also eliminated the six 
fold increase in sclerosed glomeruli in the diabetic animals during the 
14 months of follow-up. Micropuncture studies suggested that amelioration 
of glomerular capillary hypertension by enalapril was the cause of the 
protective effect against renal damage. However, Zatz et al 1986 study did 
not compare an ACE inhibitor with an alternative antihypertensive agent. 
Table XVI- Result of 10 published studies of the effects of ACE inhibition in 
patients with diabetes mellitus 
Number of Diabetes Time Drug. BP L'rinary Glucose Serum GFR RPF FF 
patients type montlis mm Hg protein tole- rrea-
rancc t jnine 
,* 
Short-term studies 
Taguma el a l . l985 10 
D'Angelo et a l . l986 10 
10 
Hommel et a l . l986 1 6 
Matthew et a l . l986 1 3 
Dominguex et a l . l986 8 
Sullivan et al . l986 10 
Winocour et a l . l985 8 
1 
1 
1 1 
1 
1 I 
1 1 
1 + 11 
1 
3 C 
3 C 
3 C 
3 
1.5 
3 
3 
1.5 
C 
C 
c 
c 
c 
-5/-3 
-19 .4 
- 2 3 . 7 
NC 
NC 
-12/-8 
- 1 9 - 1 4 NR 
-43 -12 NR 
-14 -8 NR 
NC 
NC NC 
NC 
NC 
NC 
NC NR 
improved NC 
NC NC 
NR 
NR 
NC 
NC 
NR 
NR 
NR 
NR 
NC 
NC 
NR 
NR 
NR 
NR 
NR 
NC 
NC 
NR 
NR 
NR 
NR 
NC NC NC 
Long-term studies 
Bjorck et al,1986 
Pass et a l . l987 
Marre et a l . l987 
14 
1 1 
10 
1 
1 
1 + 11 
12 
12 
6 
C 
E 
E 
-5 
-32/-19 
-13/-10 
NC 
NC 
. 
NC 
NC 
NC 
NC 
NR 
NC 
NC 
NC 
+ 
-
NR 
+ 
-
NJJ 
NC 
NC = No change: NR = not reported: +=increased: -=decresed: C=captopril: E=enalapril: RPF = renal plasma flow: 
FF=filtration fraction 
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Jackson et al, 1987 evaluated alternative treatment in diabetic rats. After 
3 months of enalapril treatment, they found that protein excretion was 
lower than after verapamil administration. However, blood pressure was 
slightly higher in the verapamil group which confounded interpretation. 
Recently Fugihara et al 1987, in a preliminary report compared hydralazine 
and enalapril treatment in diabetic rats and observed that both drugs are 
equally effective in reducing blood pressure, but only enalapril reduced 
urinary protein excretion. Enalapril was, in fact, remarkably effective, leading 
to a urinary protein level below that found in normal aging rats. A number of 
studies examined the effect of ACE inhibitors on renal function in 
diabetic patients. Taguma et al, 1985 reported that captopril induced a 
pronounced reduction in severe proteinuria in 10 patients with diabetic 
nephropathy. This effect occured in the presence of an unchanged blood 
pressure and serum creatinine. They proposed that the antiproteinuric action 
of the drug was due to renal hemodynamic changes apart from the 
hypotensive effect. The study was criticized, however, because of the presence 
of concomitant diseases, poor renal function measurements, and other 
simultaneous therapeutic maneuvers (O'Hare, 1986, Ross, 1986, Sridhar 
et al 1986, Elving et al 1986, Sawick et al, 1986). 
A great reduction in urinary protein excretion has not been found by 
others (Table XVI ). Hommel et al 1986, documented a significant 8% decrease 
in mean arterial blood pressure, followed by a 32% reduction in albuminuria, 
and a minor decline in GFR and concluded that the reduction in proteinuria 
did not exceed that which could be expected from reduced blood pressure 
in diabetes. On the other hand Marre et al, 1987 found that long-term 
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enalapril treatment resulted in both an increasein GFR and a reduction in 
proteinuria in incipient diabetic nephropathy. However, antihypertensive 
treatment with other drugs that lower blood pressure to within the 
normotensive range can also reduce microalbuminuria (Christensen et al 1985). 
In other studies (D'Angelo et al, Winocour et al, 1986, Parsa et al 1987), 
ACE inhibition had no adverse effects on GFR in the presence of significant 
reduction in blood pressure (Table XVI ). Renal plasma flow has been reported 
as unchanged or increased (Table XVI ) [Bjorck et al 1986, Martz et al, 1987, 
D'Angelo et al, 1986, Winocour et al 1986]. 
In view of the fact that the Renin-angiotensin system can be active 
even in advanced diabetic nephropathy (Bjorck et al 1984), and that ACE 
inhibition appears to induce beneficial renal hemodynamic changes even 
when renal function is impaired (Bjorck et al, 1983). Bjorck et al 1986 
prospectively studied the effect of captopril on the rate of decline in 
kidney function. In 14 patients with diabetic nephropathy, antihypertensive 
treatment reduced the rate of decline in kidney function from 10.3 to 
5.5 ml/min/year. Furthermore, during the latter part of the observation period, 
the decline in kidney function was only 2.4 ml/min/year, which is very low for 
this degree of blood pressure control. This study thus supports that ACE 
inhibition might preserve kidney function in diabetic nephropathy. However, 
it is important to note that other factors may also have contributed, such as 
a slight improvement in blood pressure or unrecognized changes in metabolic 
control. Also, the experimental design, which used patients as their 
own controls, add an element of uncertainty to the assumption that the rate of 
progression is linear (Parving H-H et al, 1987, Mogensen, 1982). 
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Although many investigators have tested ACE inhibition because 
of their renal hemodynamic effects, there may be other benficial effects. 
recently, enalapril as well as other antihypertensive dmgs have been shown to 
decrease growth of mesangial cells both in vivo and in vitro (Forgo et al, 1988). In 
addition, lipid abnormalities may be important for the progression of renal 
disease (Kasiske et al, 1988). The neutral action ACE inhibitors in this respect 
may also prove beneficial. The direct effects of ACE inhibitors on glomerular 
resistance (Zatz et al, 1986, Anderson et al, 1989) could explain the decrease of 
microalbuminuria without change in systemic blood pressure, as had been 
observed in the present study and also reported in normotensive IDDM 
patients treated with ACE inhibition (Mathiesen et al, 1991, Rudber et al 
1990). We also found a significant increase in plasma renin activity during 
enalapril treatment indicating substantial ACE inhibition and a good 
compliance. Others did not find a significant difference (Minram et al 1988, 
Slomowitz et al, 1990), perhaps because of anomalous renin secretion 
described in diabetic patients (Tuck et al, 1989). 
Our present study in patients of Type II diabetes mellitus 
corroborates previous evidence and also the observation reported by Ravid et al 
1993, about the antiproteinuric effect and the renal protective effect of ACE 
inhibition in early diabetic nephropathy in normotensive patients of Type II 
diabetes also. This effect is long-lasting and possibly additional to as well as 
independent of the antihypertensive effect of these agents. 
It is not known whether ACE inhibitors are equally effective in 
reducing mortality. The long-term administration of ACE inhibitors 
should be considered seriously in both Type I and Type II diabetes mellitus 
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with microalbuminuria, regardless of their blood pressure. After completion of 
the study, all patients in the placebo group were switched over to ACE 
inhibitor, enalapril. 
We conclude that ACE inhibitor, enalapril postpones the develop-
ment of clinical nephropathy in Type I and Type II diabetic patients with 
persistent microalbuminuria, however, longer period of observation is required 
to see if this will be helpful in preservation of normal GFR and improve the 
survival of the patients. 
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CONCLUSION 
To evaluate the long-term effect of angiotensin-converting enzyme 
inhibitor, enalapril in preventing the development of diabetic nephropathy 
(albuminuria > 300 mg/24 h), a total of 176 diabetic patients (Type I (n =73), 
Type II (n = 103) } were followed for 5 years. The design of the study was 
randomized, double - blind, placebo - controlled trial. 
Seventythree normotensive. Type I diabetic patients with 
microalbuminuria and normal renal function were randomly assigned to receive 
enalapril lOmg/day, or placebo. Any increase in blood pressure was treated 
with long-acting nifedipine. The subjects were evaluated for albuminuria, 
blood pressure, fasting plasma glucose, and glycosylated hemoglobin levels, 
every 3 to 4 months and yearly measurement of glomerular filtration rate, renal 
plasma flow and plasma renin activity. 
Clinical and laboratory variables were comparable at baseline. In the 
patients treated with enalapril, albuminuria decreased from 98 ± 51 (mean ± 
SD) mg/24 h to 49 ± 17 mg/24 h during the first year. Thereafter, we observed 
a slow decrease to 71 ± 46 mg/24 h after 5 years. In the placebo group, 
albuminuria increase from 105 ± 33 mg/24 h to 230 + 89 mg/24h after 5 years 
(difference in rate of change in albuminuria (p < 0.05). Three of the 37 (8%) 
enalapril treated patients progressed to diabetic nephropathy, whereas 11 of the 
36 (31%) placebo - treated patients developed clinical overt diabetic 
nephropathy (p < 0.05). Besides 6 of 11 placebo treated patients had evidence 
of coronary heart disease. Systemic blood pressure, glomerular filtration rate, 
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renal plasma flow, glycosylated hemoglobin concentration and urinary 
excretion of urea remained practically unchanged in the two groups. 
One hundred and three normotensive, Type II diabetic patients with 
microalbuminuria and normal renal function were also randomly assigned to 
receive enalapril 10 mg/day, or placebo. Any increase in blood pressure was 
treated with long -acting nifedipine in this group also. The subjects were 
evaluated for albuminuria, blood pressure, fasting plasma glucose, and 
glycosylated hemoglobin levels, every 3 to 4 months and yearly measurement 
of glomerular filtration rate, renal plasma flow and plasma renin activity. 
Clinical and laboratory variables were comparable at base line. In the 
patients treated with enalapril, albuminuria decreased fi-om 90 ± 48 (mean ± 
SD) mg/24 h to 80 ± 45 mg/24 h during the first year. Thereafter, we observed 
a slow decrease to 48 ± 85 mg/24 hr after 5 years. In the placebo group, 
albuminuria increased from 86 ± 45 mg/24 h to 169 ± 130 mg/24 h after 5 
years. (Difference in rate of change in albuminuria (p < 0.05). Four of the 52 
(8%) enalapril treated patients progressed to diabetic nephropathy, whereas 12 
of the 51 (24%) placebo - treated patients developed clinical overt diabetic 
nephropathy (p< 0.05). Besides 8 of 12 placebo - treated patients had evidence 
of coronary heart disease. Systemic blood pressure, glomerular filtration rate, 
renal plasma flow, glycosylated hemoglobin concentration and urinary 
excretion of urea remained practically unchanged in the two groups. 
The findings suggest that the institution of angiotensin - converting 
enzyme inhibitor, enalapril during early stages of diabetic nephropathy 
postpones the development of clinical overt diabetic nephropathy in 
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normotensive diabetic patients witli persistent microalbuminuria. These effects 
are probably independent of the antihypertensive action of these agents. 
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